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1. Introduction 
Cancer is an uneven swelling, rough, unseemly, darkish, painful, and some-
times without ulceration…and if operated upon, it becomes worse…and 
spreads by erosion; forming in most parts of the body, but more especially in 
the female uterus and breasts. It has the veins stretched on all sides as the an-
imal the crab (cancer) has its feet, whence it derives its name. 
Paul of Aegina, o.D. (c. 625 – c. 690)                   
The Seven Books of Paulus Aegineta  
1.1. Cancer statistics 
Since the description of cancer by Paulus Aegineta 1300 years have passed. Through-
out the centuries cancer has been of interest for many scientists (Ritu Lakhtakia, 2014).  
Due to the enormous expansion of knowledge over the time periods we now know 
much more about this type of disease. However, despite the huge medical and tech-
nical development, cancer is the second leading cause of death worldwide. For 2018 
the International Agency for Research in Cancer (IARC) estimated a rise of the global 
cancer burden to 18.1 million cases and 9.6 million cancer deaths (Fig. 1).  
 
Figure 1: Estimated number of new cases and cancer deaths worldwide in 2018.   
Statistics include all cancers, both sexes, all ages.  
Data source: GLOBOCAN 2018; Graph production: Global Cancer Observatory (http://gco.iarc.fr/) 
© International Agency for Research on Cancer 2018. 
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Both, cancer incidence and mortality rapidly forced up over the last decades. Today 
about 1 in 6 deaths is attributed to cancer (WHO, 2018). The reasons for this increase 
are diverse: the aging and growth of the population as well as the distribution of the 
main risk factors certainly contribute to this progression (Bray et al., 2018). In 2018, 
nearly 50 % of all cancer cases and over 50 % of the cancer deaths occurred in Asia 
(Fig.1). The fact that close to 60 % of the global population resides there, explains this 
phenomenon in part. 
However, Europe only harbors 9 % of the global population and in return accounts for 
23.4 % of the total cancer cases and 20.3 % of the total cancer deaths (Bray et al., 
2018). Due to this numbers it is obvious that suffering of cancer is not only a statistical 
probability. The risk factors for developing cancer are versatile. 25 % of cancer cases in 
low- and middle-income countries are caused by infections, such as hepatitis and hu-
man papilloma virus (HPV). Tobacco or alcohol use as well as an unhealthy diet and 
physical inactivity are not only flashpoints for noncommunicable diseases, but also 
major cancer risk factors. Around 33 % of cancer deaths are due to the five leading 
behavioral and dietary risks: high body mass index, low fruit and vegetable intake, lack 
of physical activity, tobacco and/or alcohol abuse (WHO, 2018).    
 
Figure 2: The five most commonly diagnosed cancer types worldwide in 2018.  
Statistics include all cancers, both sexes all ages.  
Data source: GLOBOCAN 2018; Available at Global Cancer Observatory (http://gco.iarc.fr/) 
© International Agency for Research on Cancer 2018.  
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Tobacco abuse is responsible for approximately 22 % of cancer deaths and thus the 
most important risk factor for cancer. So it is not astonishing, that lung cancer is the 
most prominent cancer type among adults (Fig. 2). In 2018 the five most commonly 
diagnosed cancer types were lung cancer (11.6 %) closely followed by breast cancer 
(11.6 %), colorectal (10.2 %), prostate (7.1 %) and gastric cancer (5.7 %) (Fig.2). The 
most lethal cancer types among adults were lung (18.4 %), colorectal (9.2 %), gastric 
(8.2 %), hepatic (8.2 %) and breast cancer (6.2 %) (Fig.2). 
Although tumors of the brain and the nervous system are rather unusual among adults 
(2 %) (GLOBOCAN 2018), they are the second most common diagnosed types of cancer 
in childhood. After leukemia (28.6 %), tumors of the brain and nervous system are on 
second place (11 %), followed by non-Hodgkin lymphoma (8.4 %), Hodgkin lymphoma 
(5.1 %) and renal disease (4.7 %) (Fig.3). 
 
Figure 3: Estimated number of new cases and cancer deaths worldwide in 2018.   
Statistics include all cancers, both sexes, ages <19 years.  
Data source: GLOBOCAN 2018; Graph production: Global Cancer Observatory (http://gco.iarc.fr/) 
© International Agency for Research on Cancer 2018. 
 
In the central nervous system (CNS) meningioma and gliomas are the most frequent 
types of brain tumors and account for 30 % of all brain and central nervous tumors and 
80 % of all malignant intracranial tumors (Goodenberger & Jenkins RB, 2012). Gliomas 
are further categorized by their cell origin like astrocytes or oligodendrocytes. Addi-
tionally, the World Health Organization defines four grades of classified tumors by 
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their proliferation, migration and invasion behavior (Vigneswaran et al., 2015). They 
differentiate among: 
- Grade I, bordered tumors  
- Grade II, tumors which diffusely infiltrate surrounding tissue, but with no or 
just low mitosis and necrosis such as astrocytomas or oligodendrogliomas 
- Grade III, highly infiltrating tumors with increased mitotic activity but no necro-
sis or vascular proliferation like anaplastic-astrocytomas/oligodendrogliomas 
- and Grade IV, infiltrating tumors with necrosis and micro-vascular proliferation 
as well as a high rate of mitosis, called glioblastomas (Taal, Bromberg & Van 
den Bent, 2015, Fig. 4)  
 
Figure 4: Categorization of gliomas.  
(Taal, Bromberg & Van den Bent, 2015 [modified]) 
 
1.2. Cancer treatment 
By now a lot of new therapy approaches, so-called targeted therapies (Krebsgesell-
schaft, 2019), have been developed but the surgical intervention, radio- and chemo-
therapy are still standard methods. For superficial or well-delimited cancer types like 
skin- or breast cancer, the surgical excision is the first method of choice. Though, in a 
lot of cases the tumorous tissue is not very well differentiated and a complete elimina-
tion rarely successful. Especially for gliomas, a surgical excision is, through the mainly 
intracranial location, extremely risky. However, there are often remaining cancer cells, 
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which can lead, due to their fast and invasive growing behavior (grade IV, Fig.4), to a 
rapid recrudescence. Therefore, radio-, chemotherapy or a combination of both fol-
lowing upon excision are frequently used (Krebsgesellschaft, 2019).  
1.2.1. 5-Fluorouracil 
Antimetabolites represent a large group of anticancer agents that structurally are simi-
lar as natural molecules, but differ enough to interfere with their metabolism.  
1954 Rutman et al. described that rat hepatoma cells incorporated uracil more actively 
than the normal liver cells for nucleic acid pyrimidine biosynthesis (Rutman et al., 
1954). These observations led to an idea, how tumor cells can be influenced by their 
nuleic acid biosynthesis. In the 1950’s Heidelberger et al. developed a pyrimidine ana-
log based on uracil. The name of the antimetabolite 5-Fluorouracil (5-FU) indicates that 
instead of the usual hydrogen atom at C5-position a fluorine atom is bound (Heidel-
berger et al., 1957) (Fig.4).  
                          
 
Figure 5: Constitutional formula of uracil and 5-Fluorouracil (5-FU). 
 
The following years different scientific groups (Bosch et al., 1958; Chaudhuri et al., 
1958; Dannberg et al. 1958) tried to figure out, what the cellular mechanism behind 
the effect of 5-FU is. Today it is known that the cells take up 5-FU to synthesize several 
active metabolites (Weiss et al., 2014; Fig. 5), e.g. fluorodesoxyuridine monophosphate 
(FdUMP), fluorodesoxyuridine triphosphat (FdUTP) as well as fluorouridine triphosphat 
(FUTP) (Longley et al. 2003). 
Uracil 5-Fluorouracil 
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Figure 6: Intracellular bio-functionalization of 5-FU to generate cytotoxic metabolites  
(Weiss et al. 2014[modified]). 
FdUMP and FUMP are then used as basic components and integrated into the DNA or 
RNA (Marin-Vicente et al., 2013). In addition, the synthesized FdUMP together with 10-
methylentetrahydrofolate (CH2THF) bind the thymidylate synthase, causing an irre-
versible inhibition. This leads to an interruption of the synthesis of deoxythymidine 
monophosphate (dTMP) out of deoxyuridine monophosphate (dUMP) (Grogan et al. 
2011). Due to this blocked synthesis of dTMPs, the sensible balance of deoxynucleo-
tides is disturbed. 
Auxiliary, due to the inhibition of the thymidylate synthase an accumulation of dUTP 
within the cells occurs (Aherne et al., 1996). The hoarded dUTPs and the affiliated 
FdUTPs are then spuriously used as component for the assembly of the double-strand 
DNA, causing severe damage to the DNA. The emerging strand breaks and the incor-
rect DNA synthesis lead to an activation of the uracil-DNA-glycosylase (Lindahl, 1974). 
This enzyme in turn tries to rescue the wrong assembled DNA strand by removing the 
dUTPs or FdUTPs. But, due to the imbalance of desoxynucleotides, DNA repair mecha-
nisms are also faulty (Longley et al., 2003). 
Another effect following upon 5-FU application is the integration of the 5-FU metabo-
lite FUTP into the RNA (Pettersen et al., 2011). Thereby the functions of the transfer 
RNA (tRNA) and the small nuclear ribonucleic acid (snRNA), as well as the splicing of 
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the pre-messenger (m)RNA are remolded, resulting in an impairment of the normal 
RNA-function (Santi & Hardy, 1987; Patton, 1993; Doong & Dolnick, 1988).  
At the end, all these effects appear to diminish cell proliferation and seem to trigger 
cell death (Beck et al., 1986; Kufe et al., 1981).   
Although until today it is not completely clarified or precisely understood how 5-FU 
works, it is used for the therapy of stable tumors, like gastric adenocarcinomas, colon 
and breast cancer (Bodner-Adler et al., 2007; Carrato, 2006; Khosravi Shahi et al., 
2007). Due to the fast degradation within the liver, the half-life of 5-FU within the 
blood is only a few minutes. More than 80 % of 5-FU are eliminated by the enzyme 
dihydropyrimidine dehydrogenase (Diasio & Harris, 1989; Cheng et al., 2012).  
Unfortunately, 5-FU does not only specifically target fast proliferating cancer cells. 
Therefore, it carries along aggravating side effects (Lévi et al., 1998; Wettergren et al., 
2012). Looking at these unpleasant side effects, there must be a consideration of the 
helpful effects against tumors and the consequences for the rest of the healthy cells. 
Thus, chemotherapeutic drugs are usually given in low dosages to keep the balance 
between the positive and negative outcome. 
To escape this dilemma, there is always the effort to develop novel drugs with an im-
proved effectivity. However, one crucial limiting factor of the effectiveness of such 
molecules, used in cases of neuroectodermal cancer, is the blood-brain barrier. This 
barrier is formed by astrocytes and endothelial cells, which are connected by tight 
junctions with an extremely high electrical resistivity of at least 0.1 Ω⋅m. The blood–
brain barrier restricts the passage of pathogens, the diffusion of large or hydrophilic 
molecules into the cerebrospinal fluid, while allowing the diffusion of hydrophobic 
molecules (O2, CO2, hormones) and small polar molecules (Johansen et al., 2017). 
Moreover the selective transport of molecules such as glucose and amino acids, which 
are crucial to neural function, is regulated. Beyond that, the blood-brain barrier pre-
vents the entry of lipophilic, potential neurotoxins by way of an active transport mech-
anism mediated by P-glycoprotein (Butt et al., 1990) 
Beside this, other limiting factors are the resorption properties of the cells and the 
blood supply of the tissue. The possibilities to manipulate the last two parameters are 
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rather restricted. In contrast the characteristics like lipo- and water solubility or the 
size of chemotherapeutic drugs can be modified in different ways. Rosemeyer et al. 
focus on the generation of new 5-FU derivatives, which expose a better effectivity 
(Malecki & Rosemeyer, 2010; Rosemeyer et al., 2012; Rosemeyer & Malecki, 2012; 
Köstler et al., 2013; Malecki E. 2013; Malecki et al., 2013; Malecki, Viere & Rosemeyer, 
2013; Malecki et al., 2014; Werz et al. 2013; Farhat et al., 2014; Knies et al., 2015a; 
Knies et al., 2015b; Farhat, 2016; Knies et al., 2016; Hammerbacher et al., 2018; Knies 
et al., 2018; Rosemeyer et al., 2019; Reuter et al., 2019). Taking a look at a model of 
such a uridine derivative (Fig. 7) several structural groups appear to be changeable. 
The basic module in the center (green) can be formed by a purine or pyrimidine struc-
ture. Beside this, there are three side groups (yellow, blue, pink) which influence the 
solubility of the molecule and thus contribute to an improvement of the uptake into 
the cell or passage through the blood brain barrier. These groups can vary in size (C-
chain length), hydrophobic parts (O, OH–groups) and saturation of the C-chain (C=C). 
 
Figure 7: Basic structure of a uridine derivative. 
The basic module is colored in green and the different changeable side groups are shown in 
blue, yellow and pink (Knies & Rosemeyer, 2015 [modified]). Beside the chemical structure of 5-
FUrd (A), formycin (B), adenosine (C), cladribin (D), guanosine (E) and inosine (F) are illustrated.  
For the generation of new nucleolipids the research group of Prof. Rosemeyer used 5-
Fluorouridine as well as other substances like adenosine, cladribin, formycin, guano-
sine and inosine (Fig. 7) to synthesize more than 120 novel nucleolipids.  
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1.3. Aim of the thesis 
In this study the cytotoxic effects of these novelly synthesized nucleolipids are analyzed, to 
find out whether these derivatives are more efficient for the treatment of neuronal cancer 
cells than 5-FUrd, a metabolite of 5-FU. 5-FU, which is one of the usually utilized chemo-
therapeutics, is effective on fast proliferating cancer cells. But it causes a broad range of 
adverse side effects in multiple organ systems. Beside this, 5-FU seems to induce neuron 
damage in the CNS (Han et al., 2008). To eliminate these unwanted side effects and to gain 
a better effectivity, Rosemeyer et al., synthesized in a cooperative project a series of modi-
fied 5-FUrd, adenosine, cladribin, formycin, guanosine and inosine derivatives (Malecki & 
Rosemeyer, 2010; Rosemeyer et al., 2012; Rosemeyer & Malecki, 2012; Köstler et al., 
2013; Malecki E. 2013; Malecki et al., 2013; Malecki, Viere & Rosemeyer, 2013; Malecki et 
al., 2014; Werz et al. 2013; Farhat et al., 2014; Knies et al., 2015a; Knies et al., 2015b; Far-
hat, 2016; Knies et al., 2016; Hammerbacher et al., 2018; Knies et al., 2018; Rosemeyer et 
al., 2019; Reuter et al., 2019). These derivatives have different additional chemical side 
groups, which influence mainly their water and lipid solubility. By that, the permeability 
across the blood-brain-barrier as well as the uptake by the cells is intended to be im-
proved. 
The first part of this thesis screens the impact of the 120 novelly synthesized nucleolipids, 
in comparison to 5-FUrd, on the viability of rat BT4Ca and human GOS3 glioma cells used 
as a model for neuronal cancer cells (Graphic 1). Additionally, the occurrence of possible 
side effects are analyzed by using the human THP-1 derived macrophages representing 
tumor associated immune cells. The novelly synthesized derivatives which are not too 
harmful for the macrophages and reveal an increased or a similar cytostatic/cytotoxic ef-
fect compared to 5-FUrd towards both tested glioma cell lines (BT4Ca and GOS3), are ex-
amined on several other tumor entities, too (Graphic 1). The second part of the study fo-
cuses on the investigation of effects of the five most interesting derivatives and 5-FUrd. In 
this context, our goal is to find out, which way of cell death is related to the potentially 
observed cytotoxic effects and if the active derivatives have an impact on the induction of 
apoptosis, necrosis, oxidative stress, NFκB, proliferation and migration in the rat BT4Ca 
glioma cells used as a model cell line (Graphic 1). Thus, the signaling of the novelly synthe-
sized nucleolipids (and 5-FU) is even more precisely specified. Finally, we intend to identify 
derivatives with the potential to combat cancer, at best more efficient than conventional 
chemotherapeutics like 5-FU. 
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1.4. Schematic layout of the thesis 
 
 
 
Graphic 1: Schematic layout of the thesis. The flowchart illustrates the work process of the thesis.  
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2. Material 
2.1. Instruments/Equipment 
Instruments Producer 
Autoklav Heratherm Oven OMS 100 Fisher Scientific GmbH, Schwerte 
AxioCam MRm Camera Carl Zeiss AG, Oberkochen Germany 
Centrifuge Perfect Spin P PEQLAB Biotechnologie GmbH, Erlangen, 
Germany 
Centrifuge Pico 17 Heraeus Holding GmbH, Hanau, Germany 
Camera AxioCam MRc Carl Zeiss AG, Oberkochen Germany 
Confocal laser scanning microscope 
Nikon Eclipse Ti 
Nikon GmbH, Geschäftsbereich Mikrosko-
pe 
Düsseldorf Germany 
Cytation™ 3 microplate  reader BioTek Instruments, Inc., headquartered in 
Winooski, VT, USA. 
Fusion-SL 3500.WL Imaging System PEQLAB Biotechnologie GmBH, Erlangen, 
Germany 
Ice-Crasher  Scotsman  AF103 Kaelte-kameath GmbH & Co.KG, Linden, 
Germany.  
Incubator B 5042 Heraeus Holding GmbH, Hanau, Germany 
Kern KB 3600-2N Precision balance 
0,01 g : 3600 g 
Kern & Sohn GmbH, Balingen, Germany 
Multipette® plus Eppendorf AG, Hamburg, Germany 
Nikon Eclipse TS100 Inverted Micro-
scope 
Nikon GmbH, Düsseldorf, Germany 
Pipetman Classic™ P10, P20, P100, 
P200, P1000 
Gilson Inc., Middleton, USA 
PowerEase® 500 Power Supply Invitrogen, Eugene, USA 
Promax 1020 Shaker Heidolph Instruments GmbH & Co. KG, 
Schwabach, Germany 
Sunrise microplate reader Tecan Group Ltd;  Männedorf, Switzerland 
Thermoshaker PHMT-PSC-18 Grant Instruments Ltd., Cambridge, UK 
Ultrasonic bath Sonorex BANDELIN electronic GmbH & Co. KG, Ber-
lin, Germany 
Ultrospec III, UV Visible Spectropho-
tometer 
Pharmacia Biotech Inc. Massachusetts, 
USA 
Vortexer MS 3 IKA®-Werke GmbH & CO. KG, Staufen, 
Germany 
Zeiss Axiovert 135 (inverted 
epiflourescence microscope) 
Carl Zeiss AG, Oberkochen, Germany 
Table 1: List of instruments 
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2.2. Consumption items 
Material Company 
6-well tissue culture plate Bectin Dickinson Labware, Franklin La-
kes, USA 
96- well- plate (cell culture) BD Falcon™, Becton Dickinson GmbH, 
Heidelberg, Germany 
C-Chip DHC-N01 Digital Bio;  Hopkinton, USA 
Cell Scraper 300 mm TPP Techno Plastic Products AG, Tra-
sadingen, Switzerland 
Disposable Cuvettes 1.5 ml BRAND GMBH + CO KG, Wertheim, Ger-
many 
Filtertips, 1-1000 µl, steril SARSTEDT AG & Co., Nümbrecht, Ger-
many 
Filtertips, 5-10 ml SARSTEDT AG & Co., Nümbrecht, Ger-
many 
Lumox® multiwell, 96- well plate SARSTEDT AG & Co., Nümbrecht, Ger-
many 
Microcentrifuge Tube w/lid, 0.5 ml BrandTech Scientific Inc., Essex, UK 
Nobaglove-Nitril NOBA Verbandmittel Danz GmbH u. Co 
KG, Wetter, Germany 
PARAFILM® “M”  Pechiney Plastic Packing, Chicago Il., USA 
Safe Seal Micro Tube, 1.5 ml und 2 ml SARSTEDT AG & Co., Nümbrecht, Ger-
many 
TC-Flask T175 Stand.,Vent. Cap. SARSTEDT AG & Co., Nümbrecht, Ger-
many 
TC-Flask T75 Stand.,Vent. Cap. SARSTEDT AG & Co., Nümbrecht, Ger-
many 
Tube, 15 ml und 50 ml SARSTEDT AG & Co., Nümbrecht, Ger-
many 
Table 2: List of consumption items 
 
2.3. Reagents and substances 
Reagents/ substances Company 
2-Amino-2-(hydroxymethyl)propane-
1,3-diol (Tris) 99.9% PA 
Carl Roth GmBH & Co. KG, Karlsruhe, 
Germany 
5-Fluorouracil (F6627) 20mM Sigma-Aldrich Co. LLC, ST. Louis, USA 
5-Fluorouridine (F0636) 20mM TCI Europe, Zwijndrecht, Belgien 
5-Sulfosalicyl acide dihydrate (SSA) Sigma-Aldrich Co. LLC, ST. Louis, USA 
Camptothecin  Cayman Chemicals, Biomol GmbH 
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Hamburg, Germany 
CellEventTM Caspase-3/7 Green Detec-
tion Reagent, 2mM   
Invitrogen, Eugene,USA   
Dimethyl sulfoxide (DMSO) MERCK-Schuchardt, Hohenbrunn, Ger-
many  
DMEM low Glucose (1g/l) PAA Laboratories GmBH; Pasching, Ger-
many 
Dulbecco's Modified Eagle Medium 
(DMEM) High Glucose (4.5g/l) 
Capricorn Scientific GmbH; Ebsdorfer-
grund, Germany 
Dulbecco's Phosphate-Buffered Saline 
PBS  (1x) (without Ca & Mg) 
Capricorn Scientific GmbH; Ebsdorfer-
grund, Germany 
EDTA (ethylene diamine tetraacetic ac-
id) 
Thermo Scientific, Schwerte, Germany 
Ethanol 70 % AppliChem GmbH, Darmstadt Germany 
Ethanol 96 %  Sigma-Aldrich Co. LLC, ST. Louis, USA 
Fetal bovine serum (FBS) Capricorn Scientific GmbH; Ebsdorfer-
grund, Germany 
High-purity sodium chloride (NaCL > 
99.8%) 
Carl Roth GmBH & Co. KG, Karlsruhe, 
Germany 
Hoechst 33342 16.2mM  Invitrogen, Eugene, USA 
Hydrogen peroxide 30%  Carl Roth GmBH & Co. KG, Karlsruhe, 
Germany 
Natriumhydroxide (NaOH) MERCK-Schuchardt, Hohenbrunn, Ger-
many 
Penicillin/Streptomycin 100x Capricorn Scientific GmbH; Ebsdorfer-
grund, Germany 
Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich Co. LLC, ST. Louis, USA 
PrestoBlue® cell viability reagent Invitrogen, Eugene, USA 
Propidium iodine 1.5mM Invitrogen, Eugene, USA 
Protease Inhibitor Cocktail (100X) Cell Signaling Technology, Inc., Danvers, 
USA 
Radioimmunoprecipitation assay (RIPA) 
Lysis Buffer, 10x 
Cell Signaling Technology, Inc., Danvers, 
USA 
RPMI 1640 medium (low glucose) Capricorn Scientific GmbH; Ebsdorfer-
grund, Germany 
Sulforhoadmine B sodium salt Sigma-Aldrich Co. LLC, ST. Louis, USA 
Trichloroacetic acid (TCA)>99% Carl Roth GmBH & Co. KG, Karlsruhe 
Germany 
tri-ethanolamine (TEA) ≥99.5% Carl Roth GmBH & Co. KG, Karlsruhe, 
Germany 
Triton™ X-100 Thermo Scientific, Schwerte, Germany 
Trypan blue 0.4% Sigma-Aldrich Co. LLC, ST. Louis, USA 
Trypsin-EDTA (0.05 % Trypsin; 0.02 % PAA Laboratories GmBH; Pasching, Ger-
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EDTA) many  
Tween® 20  Carl Roth GmBH & Co. KG, Karlsruhe, 
Germany 
UltraPure™ Destilled water, DNase/ 
RNase free 
Life Technologies GmbH, Darmstadt, 
Germany 
YO-PRO®-1 Iodide 1mM  Thermo Scientific, Schwerte, Germany 
Table 3: List of reagents and substances 
 
2.4. Buffers and solutions 
Buffers/solutions Recipe/Company 
2.5 % Sulfosalicylic acid (SSA) 2.5g SSA solved in sterile a.dest. 
Sigma-Aldrich Co. LLC, ST. Louis, USA 
Freezing Medium Appropriate cell culture medium contain-
ing 20% DMSO 
Glutathione buffer 0.1M Na2HPO4 * 2H2O; 5mM EDTA; pH 
7.5 
Glutathione-reductase 120units/mg 
protein 
Sigma-Aldrich Co. LLC, ST. Louis, USA 
GSH revealing solution 4.5ml SSA solved in 300ml tri-
ethanolamine (TEA) 
GSH standard 
 
0.025, 0.05, 0.1 and 0.25 nmol/ml 
Carl Roth GmBH & Co. KG, Karlsruhe, 
Germany 
GSSG standard 
 
0.025, 0.05, 0.1 and 0.25 nmol/ml 
Carl Roth GmBH & Co. KG, Karlsruhe, 
Germany 
NADPH-Tetra-Natriumsalt 
0.83mM 
Carl Roth GmBH & Co. KG, Karlsruhe, 
Germany 
Phosphate-buffered saline (PBS) 10 x 82g NaCl 
2g KCl 
15.1g Na2HPO4 
2g KH2PO4 
In 1l a.dest.  
pH 7.4 
Vinyl pyridine Sigma-Aldrich Co. LLC, ST. Louis, USA 
5,5-dithio-bis-2-nitrobenzoic acid 
(DTNB) 3mM 
Carl Roth GmBH & Co. KG, Karlsruhe, 
Germany 
Table 4: List of buffers and solutions 
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2.5. Kits 
Name Components Company 
CytoSelect™ Proliferat-
ing Cell Nuclear Antigen 
(PCNA) ELISA Kit  
Anti-PCNA Antibody Coated Plate 
Anti-PCNA Antibody (1000X) 
Secondary Antibody HRP Conju-
gate 
Assay Diluent 
10 X Wash Buffer 
Substrate Solution 
Cell Biolabs, Inc., 
San Diego, USA 
 
Pierce™ BCA Protein 
Assay Kit 
 
Reagent A 
Reagent B 
Thermo Fisher Sci-
entific Germany BV 
& Co KG, Braun-
schweig, Germany 
Table 5: List of Kits 
 
2.6. Antibodies 
Antibody Description Catalog-
number 
Company Dilution 
Primary antibody     
Anti- NFκB p65 Goat polyclonal 
to  NFκB p65 
Sc-372-G Santa Cruz Bio-
technology, Inc. 
Bergheimer Str. 
89-2, 69115 Hei-
delberg, Germany 
1:50 
Anti- PCNA     
CyTM3-conjugated 
Anti-Goat  
CyTM3-
conjugated Affin 
Pure Rabbit Anti-
Goat polyclonal 
IgG 
305165003 Jackson Immu-
noResearch Eu-
rope Ltd. 
Cambridgeshire 
CB7 4EX | UK 
1:100 
Table 6: List of primary- and secondary antibodies 
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2.7. Software 
Software / Equipment Software Company 
Confocal laser scanning micro-
scope Nikon Eclipse Ti 
NIS-Elements AR 
4.30.01 64-bit 2014 
Nikon GmbH 
Düsseldorf, Germany 
Graphical Illustration Microsoft Excel 2013 Microsoft Corporation, 
Redmond, USA 
Java-based image processing Image J 1.52a National Institutes of 
Health, Bethesda, USA 
Light- and Fluorescence micro-
scopic images  
AxioVision Release 4.8.2 Carl Zeiss, AG, Oberko-
chen, Germany 
Statistical Analyses Sigma Plot 12.0 
 
Microsoft Excel 2013 
Systat Software, Inc, 
Chicago, USA 
Microsoft Corporation, 
Redmond, USA 
Table 7: List of software
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Characteristics and the chemical structure of the five derivatives of interest are listed. The properties of these and all other tested deriva-
tives, shown in the supplements (see supplements page 174-195 Figs 52-96 and following table). , can be found in the dissertations of Dr. 
Christine Knies “Nucleolipide: Synthese und Biomedizinische Aspekte“(2017) and in Knies & Rosemeyer, 2015. 
Unmodified molecule 
Derivative Code 
Mw 
[g/mol] 
log Pow Chemical structure 
 
HN
N N
N
O
O
HO OH
HO
NL_6.0.0.0
   Inosine  
S.18 NL_6.1.13.0 598.73 
3.50 ± 
0.74 
 
 
HN
N N
N
O
O
HO OH
HO
NL_6.0.0.0
   Inosine  
S.19 NL_6.3.0.0 532.72 
5.30 ± 
0.74 
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N
N N
N
NH2
O
HO OH
HO
NL_5.0.0.0
Adenosine  
S.38 NL_5.1.13.0 598.75 
-0.79 
unit ± 
0.74 
 
 
S.98 NL_8.1.13.0 597.75 
3.61 ± 
0.74 
 
 
HN
N N
N
O
O
HO OH
HO
NL_6.0.0.0
   Inosine  
S.101 NL_6.0.3.0 472.58 
2.29 ± 
0.74 
 
 
Table 8: List of derivatives/nucleolipids under test
 Farnesyl 
 
 Farnesyl 
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2.8. Cell lines 
2.8.1. Rat BT4Ca glioma cells  
Cell line: 
Species:  
Cell type: 
Origin: 
 
 
 
 
 
Histology: 
 
Biosafety level: 
Morphology: 
Medium: 
Incubation: 
Doubling time: 
Harvest: 
Storage: 
BT4Ca 
Rat 
multipolar glia-like cells 
A kind gift from Dr. N. John, Hannover Medical School. First pub-
lished by Laerum et al., 1977: “fetal BD IX-rat brain cells (FBC), 
transferred to long-term culture after a transplacental pulse of 
EtNU on the 18th day of gestation, undergo neoplastic transfor-
mation in vitro ("BT-cell lines"). Tumors developed upon s.c. re-
implantation of BT-cells into baby BD IX-rats”. 
neurinoma-, glioma- or glioblastoma-like, and frequently as plei-
omorphic neoplasms 
1 
gliomacells, adherent cells growing as monolayer 
90% Dulbecco's MEM + 10% h.i. FBS + P/S 
at 37 °C with 5% CO2 
ca. 12 hours  
at saturation density  
frozen with 70% medium, 20% FBS, 10% DMSO 
        Source: (Laerum et al., 1977) 
2.8.2. Human GOS-3 glioma cells 
Cell Line: 
DSMZ no.: 
Species: 
Cell type: 
Origin: 
 
 
 
 
 
 
 
 
Reference(s): 
Biosafety level: 
Permissions and 
restrictions: 
GOS-3  
ACC 408 
human (Homo sapiens)  
glioma (derivative of U-343-MG) 
originally described as a glioma cell line established from the tu-
mor material of brain from a 55-year-old man with a mixed astro-
oligodendroglioma (grade II/III); however, DNA fingerprinting at 
DSMZ showed clearly that this cell line is in reality a derivative of 
the human glioma cell line U-343-MG; described to express neu-
roepithelial markers GFAP, vimentin and S-100 protein as well as 
pp60C-SRC, but not the neuro-specific variant pp60C-SRCN and to 
express neuropoietic factors CNTF, LIF and their receptors; LIF 
and oncostatin M induce growth inhibition and differentiation 
14590, 14591, 19087 
1 
A 
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DSMZ Cell Culture Data: 
Morphology: 
Medium: 
Subculture: 
 
 
Incubation: 
Doubling time: 
Harvest: 
 
Storage: 
fibroblastoid, adherent cells growing as monolayer 
90% Dulbecco's MEM + 10% h.i. FBS + 4 mM L-glutamine +P/S 
split confluent culture 1:2 to 1:3 every third day using tryp-
sin/EDTA; maintain at 7-10 x 106 cells/175 cm2; seed out at ca. 1 x 
106 cells/25 cm2 in 10 ml medium 
at 37 °C with 5% CO2 
ca. 50 hours 
cell harvest of ca. 10-15 x 106 cells/175 cm2; maximal density of 
17 x 106 cells/175 cm2 
frozen with 70% medium, 20% FBS, 10% DMSO 
        Source: (DSMZ, 2019) 
2.8.3. Human G28 glioma cells 
Cell line: 
Synonyms: 
Accession: 
Resource Identifica-
tion Initiative: 
Disease: 
Species of origin: 
Hierarchy: 
Sex of cell: 
Category: 
G 28 
NCE G-28; NCE-G28; G-28; G28; NeuroChirurgie Eppendorf-
Glioma 28 
CVCL_N724 
 
To cite this cell line use: NCE-G 28 (RRID:CVCL_N724)  
Gliosarcoma (NCIt: C3796) 
Homo sapiens (Human) (NCBI Taxonomy: 9606) 
Children: CVCL_0V15 (NCE G-28T) 
Male 
           Source: (ExPASy, 2019b) 
2.8.4. Human G112 glioma cells 
Cell line: 
Synonym: 
 
Accession: 
Resource Identifica-
tion Initiative: 
Comments: 
 
Disease: 
Species of origin: 
Sex of cell:  
Category: 
G112  
NCE G-112; NCE G 112; NCE-G112; G-112; G112; NeuroChirurgie 
Eppendorf-Glioma 112  
CVCL_N740 
 
To cite this cell line use: NCE-G 112 (RRID:CVCL_N740) 
Omics: Deep RNAseq analysis. 
Omics: SNP array analysis. 
Glioma (NCIt: C3058)  
Homo sapiens (Human) (NCBI Taxonomy: 9606) 
Male 
Cancer cell line 
                Source: (ExPasy, 2019) 
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2.8.5. Human U87 glioma cells 
Cell line: 
Synonym: 
Organism:  
Tissue: 
Disease: 
Biosafety: 
Age: 
Gender: 
Morphology: 
Growth Properties: 
Medium: 
 
 
 
Storage: 
U87  
ATCC® HTB14™ 
Homo sapiens, human 
brain 
Likely glioma 
1 
unknown 
male 
epithelial 
adherent 
The base medium for this cell line is ATCC-formulated Eagle's 
Minimum Essential Medium, Catalog No. 302003. To make the 
complete growth medium, add the following components to the 
base medium: fetal bovine serum to a final concentration of 10 % 
liquid nitrogen, vapor phase 
       Source: (ATCC, 2019c) 
2.8.6. Human U251 glioma cells 
Cell line:  
CLS order number:  
U251  
Cryovial: 300385  
Vital: 330385  
Origin and General Characteristics  
Organism:  
Ethnicity:  
Gender:  
Tissue:  
Morphology:  
Celltype:  
Growth Properties:  
Description:  
 
Homo sapiens (human)  
Caucasian  
Male 
Brain 
Epithelial 
Glioma  
Monolayer, adherent 
Authentication studies performed at ATCC and others, the identi-
ty of the U-373 MG cell line has been questioned.  
Authentication via STR analysis, conducted by CLS GmbH, as well 
as morphological and immunological analysis has revealed that 
U-373 MG is identical to U-251 MG. 
                     Source: (CLS, 2019) 
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2.8.7. Human HT29 (adenocarcinoma) cells  
Cell line: 
Biological source: 
Growth mode: 
Karyotype: 
Morphology: 
Products: 
 
Receptors: 
Application(s): 
 
Cell Line Origin: 
Cell Line Descrip-
tion: 
    
  
HT29 
Colon from human 
Adherent 
2n = 46, hypertriploid 
Epithelial 
Secretory component of Immunoglobulin A (IgA), Carcinoembry-
onic antigen (CEA) 
Not specified 
cell culture | mammalian: suitable  
Tumourigenicity studies 
Human Caucasian colon adenocarcinoma 
Isolated from a primary tumour in a 44 year old Caucasian fe-
male. Forms a well-differentiated adenocarcinoma consistent 
with colony primary, grade I. Tumours also form in steroid treat-
ed hamsters. Has the following HLA profile A1,3; B12,17; Cw5. 
               Source: (ATCC, 2019d) 
2.8.8. Human HepG2 (hepatocellular carcinoma) cells  
Cell line: 
Biological source: 
Growth mode:  
Karyotype: 
Morphology: 
Products: 
 
Receptors: 
Application(s): 
 
Cell Line Origin: 
Cell Line Descrip-
tion: 
 
 
 
 
  
HepG2 
Liver from human 
Adherent 
Modal no. 55 
Epithelial 
Prothrombin, antithromin III, alpha-foetoprotein complement, C3 
and C4 activator, fibrinogen 
Not specified 
cell culture | mammalian: suitable  
Study of hepatocyte function and specific protein expression 
Human Caucasian hepatocyte carcinoma 
The Hep G2 cell line has been isolated from a liver biopsy of a 
male Caucasian aged 15 years, with a well differentiated hepato-
cellular carcinoma. The cells secrete a variety of major plasma 
proteins e.g. albumin, α2-macroglobulin, α 1-antitrypsin, trans-
ferrin and plasminogen. They have been grown successfully in 
large scale cultivation systems. Hepatitis B virus surface antigens 
have not been detected. The cells will respond to stimulation 
with human growth hormone.  
       Source: (ATCC, 2019e) 
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2.8.9. Human Panc-1 (pancreatic carcinoma) cells  
Cell line: 
DSMZ no.: 
Species: 
Cell type: 
Origin: 
     
 
 
 
 Biosafety level: 
Panc-1  
ACC 783  
human (Homo sapiens) 
pancreas carcinoma 
established in 1972 from the ductal cells of a tumor located in 
the head of the pancreas of a 56-year-old man; the cells are de-
scribed in the literature to be tumorigenic in nude-athymic 
mouse, to carry three marker chromosomes and a small ring 
chromosome 
24155, 24156, 24157  
  1  
DSMZ Cell Culture 
Data:  
Morphology: 
Medium: 
    Subculture: 
     
Incubation: 
Doubling time: 
Harvest: 
   Storage: 
 
 
epithelioid cells growing adherently as monolayer 
90% Dulbecco´s MEM + 10% h.i. FBS 
seed out at ca. 1-2 x 106 cells/80 cm2 flask; split confluent cul-
ture 1:4 twice a week using trypsin/EDTA  
at 37 °C with 5% CO2  
ca. 40-45 hours  
cell harvest of ca. 18-20 x 106 cells/175 cm2 
frozen with 70% medium, 20% FBS, 10% DMSO  
   Source: (DSMZ, 2019b) 
2.8.10. Murine RenCa (renal carcinoma) cells  
Cell line: 
Description: 
Origin: 
 
 
Organism: 
Strain: 
Tissue Source: 
Cell type: 
Morphology: 
Growth Properties: 
Medium: 
 
Culture Conditions: 
 
 
 
Population: 
RenCa 
Murine Renal carcinoma cell line. 
The RenCa cell line has been established from the murine trans-
plantable renal adenocarcinoma of spontaneous origin. The spe-
cies was confirmed by Real-Time PCR. 
Mus musculus, mouse 
Balb/c 
Kidney 
Carcinoma 
Epithelial 
Monolayer, adherent  
RPMI-1640 medium supplemented with 2 mM L-glutamine and 
10% fetal bovine serum. 
Temperature: 37°C 
Atmosphere: air, 95%; carbon dioxide (CO2), 5%Quality  
Sub cultivation ratio: A sub cultivation ratio of 1:4 to 1:10 is 
recommended. Medium renewal: Every 2 to 3 days. 
Doubling Time: approximately 24 hours. 
                                                                                                                           Source: (ATCC, 2019b) 
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2.8.11. Human THP-1 (monocytic leukemia) cells / macrophages  
Cell line: 
DSMZ no.: 
Species: 
Cell type: 
Origin: 
 
 
 
 
Reference(s): 
Biosafety level: 
Permissions and 
restrictions: 
THP-1 
ACC 16 
human (Homo sapiens) 
acute monocytic leukemia 
established from the peripheral blood of a 1-year-old boy with 
acute monocytic leukemia (AML) at relapse in 1978; the cells can 
be used for induction of differentiation studies; the cells were de-
scribed to produce lysozyme and to be phagocytic; carries 
t(9;11)(p21;q23) leading to MLL-MLLT3 (MLL-AF9) fusion gene 
14493, 15021, 15022 
1 
A 
 
DSMZ Cell Culture Data: 
Morphology: 
Medium: 
Incubation: 
Doubling time: 
Harvest: 
Storage: 
round, single cells in suspension, partly in clusters; image 
90% RPMI 1640 + 10% h.i. FBS 
at 37 °C with 5% CO2 
ca. 35-50 hours 
saturation density at about 1.0 x 106 cells/ml 
frozen with 70% medium, 20% FBS, 10% DMSO 
             Source: (DSMZ, 2019c) 
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3. Methods 
3.1. Cell culture 
All experiments were performed under a sterile working bench. 
3.1.1. Cell culture conditions 
For culturing the glioma cell lines BT4Ca, GOS-3, G28, G112, U87 and U251 DMEM high 
glucose (4.5 g/l) medium, supplemented with 10 % heat-inactivated (30 minutes at 
56°C), fetal bovine serum (FBS), 100 U/ml Penicillin as well as 0.1mg/ml Streptomycin, 
was used. 
The other cell lines, THP-1, HT29, HepG2, RenCa and Panc-1, were cultured in RPMI 
1640 low glucose (1g/l) medium, supplemented with 10% heat-inactivated FBS 100 
U/ml Penicillin and 0.1 mg/ml Streptomycin (P/S). The cell cultures were maintained at 
37°C in a humidified incubator in an atmosphere of 5 % CO2 – 95 % air and passaged 
after reaching the 80-90 % confluency every 48-72 h in a 75 cm² flask with fresh medi-
um. 
3.1.2. Defrosting and freezing of cells 
The cells, which were stored in liquid nitrogen were quickly defrosted and mixed with 
10 ml fresh DMEM high glucose or RPMI 1640 low glucose medium, depending on the 
cell line. After centrifugation (10 min, 250 x g) the supernatant was removed and the 
cell pellet was resuspended in 1 ml fresh medium and added to 45 ml medium. After-
wards the cells were cultured as described above. 
For freezing the cells, pellet was resuspended with 400 µl fresh medium transferred 
into a freezing tube and cooled down on ice for 1-2 h. Afterwards 400 µl freezing me-
dium was added and the cells were stored at -80°C for at least 3 days. For longer stor-
age times the tubes were transferred into liquid nitrogen. 
3.1.3. Cell Splitting 
After the cells reached confluence, normally three to four days, the cells were cultured 
at a split ratio of 1:20 (BT4Ca), 1:5 (GOS3), 1:5 (G28), 1:3 (G112), 1:20 (U87), 1:5 
(U251), 1:3 (HT29), 1:5 (HepG2 and RenCa), 1:10 (Panc-1) and 1:10 (THP1) and trans-
ferred into another culture flask with warm (37°C) fresh medium (RPMI or DEMEM + 
10%FBS + P/S). 
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3.1.3.1. Culturing of human THP1 cells 
The non-adherent THP1 cells were transferred to a 50 ml tube and centrifuged 5 min 
at 100 x g. Subsequently the supernatant was removed and the cell pellet was resus-
pended in 10 ml warm (37°C) fresh RPMI 1640 (low glucose) medium. 1 ml of the cell-
suspension was then added to 45 ml medium in a culture flask and maintained at 37°C 
in a humidified incubator in an atmosphere of 5 % CO2 – 95 % air. 
3.1.3.2. Culturing of cancer cells 
The adherent cancer cells were at first detached by Trypsin treatment. Therefore, the 
old medium was drained off and the cells were shortly washed with 10ml DPBS. After 
removing the DBPS, 1 ml Trypsin-EDTA (0.05 % Trypsin; 0.02 % EDTA) was added into 
75 cm² culture flask to completely cover the monolayer of the cells and incubated for 
1-5 min at 37°C. The detached cells were then rinsed twice with 5 ml high glucose me-
dium and collected in a 50 ml tube. Next the cell suspension was centrifuged for 7 min 
at 200 x g and the cell pellet was resuspended in 10 ml fresh medium. Afterwards the 
cells were splitted, depending on their proliferation rate (see 3.1.1.) and maintained at 
37°C in a humidified incubator in an atmosphere of 5 % CO2 – 95 % air. 
3.1.4. Cell counting 
For further experiments a defined amount of cells, according to the area of the well, 
had to be seeded. Therefore, the cells were counted using a C-Chip, which is based on 
the improved Neubauer counting chamber principle. 10 µl of a cell suspension (see 
3.1.1.1/3.1.1.2) were mixed with 90 µl 0.4 % Trypan blue dye exclusion test (1 min) to 
determine the number of viable cells. Then, 10 µl of this cell suspension were placed 
on the C-Chips and, with the use of a light microscope (magnification 100 x), the living 
cells (Trypan blue negative) in all 4 squares were counted. Calculation of the cell con-
centration was performed by using the formula: 
𝒍𝒊𝒗𝒊𝒏𝒈 𝒄𝒆𝒍𝒍𝒔
(𝒊𝒏 𝟒𝒔𝒒𝒖𝒂𝒓𝒆𝒔)
𝟒 [𝒔𝒒𝒖𝒂𝒓𝒆𝒔]
× 𝟏𝟎 [𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏 𝒇𝒂𝒄𝒕𝒐𝒓] × 𝟏𝟎. 𝟎𝟎𝟎 [𝒄𝒉𝒂𝒎𝒃𝒆𝒓 𝒇𝒂𝒄𝒕𝒐𝒓] =
𝒄𝒆𝒍𝒍𝒔
𝒎𝒍
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3.2. Viability assay 
Cell viability was analyzed after 48h of treatment with different concentrations of the 
novelly synthesized derivatives. Distinct cell numbers were used as follows: BT4Ca 5 x 
103 cells/well, GOS3 1.5 x 104 cells/well, G28 1.5 x 104 cells/well, G112 1.5 x 104 
cells/well, U87 5 x 103 cells/well, U251 7.5 x 103 cells/well, HT29/HepG2/RenCa 10 x 
104 cells/well, or Panc-1 1.5 x 104 cells/well were seeded on a 96 well plate. Moreover, 
THP1 3.0 x 104 cells/well were seeded on a 96-well plate and differentiated into mac-
rophages for 72h with 100 nM PMA. All cell lines were cultured at 37°C in a humidified 
incubator in an atmosphere of 5 % CO2 and 95 % air. 
After 24 h the medium was changed and the derivatives were added at different con-
centrations. As negative control, the cells were cultured in medium alone. For the 
DMSO control, the cells were cultured with medium containing 0.05% DMSO (= same 
DMSO concentration as in the highest concentration (50 µM) of the derivatives). 
After 48 h treatment the medium was carefully changed and the cell viability was 
measured by using PrestoBlue® assay (see below 3.2.1).  
3.2.1. PrestoBlue® assay 
PrestoBlue® is a cell permeable, resazurin-based, blue solution, functioning as a cell 
viability indicator. Based on the reducing power of living cells a quantitative measure-
ment of the viability/cytotoxicity can be determined. After addition to the cells, the 
reagent is modified by the reducing environment of the viable cells and turns from 
blue to red color (absorbance at 570 nm and 600 nm as a reference wavelength) and  
becoming highly fluorescent at 560 nm (excitation) measured at 590 nm (emission) (Xu 
et al., 2015).
After the incubation (48h) with the derivatives under test, the medium was removed 
and 100 µl fresh medium was added. Afterwards PrestoBlue® reagent was directly 
added to the fresh medium at a final concentration of 10 %. At least 15 min after addi-
tion of PrestoBlue®, the optical density (OD) was measured with a SUNRISE ELISA-
reader (Tecan, Salzburg, Austria) or fluorescence with a Cytation™ 3 microplate reader 
(BioTek Instruments, USA), respectively. The effects of different concentrations of each 
derivative on the cell viability were measured in four replicates, whereas the mean of 
the blank (medium with PB alone) was subtracted. The assay was repeated at least five 
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times. The cells in the negative control wells were incubated with culture media alone. 
Then the viability compared to the negative control was calculated and the mean val-
ues were determined according to the formula:  
Results are expressed in % of viability: 
𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑖𝑛 % = [ 
OD570/600nm of samples × 100
OD570/600nm of control without substances
]  . 
3.2.2. Sulforhodamine B assay 
The sulforhodamine B (SRB) assay is used for cell density determination, based on the 
measurement of cellular total protein content. The method relies on the property of 
SRB, which binds stoichiometrically to proteins under mild acidic conditions. It can be 
extracted using basic conditions; thus, the amount of bound dye can be used as a 
proxy for the protein concentration or cell mass of a sample. Thereby the cytotoxicity 
of the different test derivatives and the used controls can be examined (Orellana & 
Kasinski, 2016).  
Following the PrestoBlue® assay the cells were shortly washed with PBS and fixed with 
10 % (wt/vol) trichloroacetic acid (TCA) for 30 min at 4°C. Hence the TCA was removed 
and the fixated cell monolayers were washed 3 times with water. Upon drying the 
samples were stained with 0.4 % SRB solved in 1 % (vol/vol) acetic acid for 30 min in 
the dark. The excess dye was removed by shortly washing 3 times with 1% (vol/vol) 
acetic acid. After a second drying step, the protein-bound dye was dissolved in 10 mM 
Tris base solution. At the end the OD was measured at 560 nm and 690 nm as refer-
ence using the SUNRISE ELISA-reader (Tecan, Salzburg, Austria). The protein content of 
each well after treatment with the derivatives of interest was measured in four repli-
cates and the mean of the blank (SRB reagents alone) was subtracted. The assay was 
repeated at least five times.  The cells in the negative control were incubated with cul-
ture media alone. Then the percentage of the protein content compared to the nega-
tive control was calculated and the mean values were determined according to the 
formula:   
Results are expressed in % of protein content: 
 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 𝑥 𝑤𝑒𝑙𝑙  𝑖𝑛 % = [ 
OD560/690nm of samples × 100
OD560/690nm of control without substances
]  . 
𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 𝑖𝑛 % = 100 − [ 
OD560/690nm of samples × 100
OD560/690nm of control without substances
]  
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The loss of proteins represents the cytotoxicity of the derivatives, assuming the higher 
the loss of protein the higher the cytotoxicity. 
3.3. Apoptosis and necrosis assay 
3.3.1. Apoptosis and necrosis staining 
A more detailed view on the possible mechanism of cell death was achieved by per-
forming an apoptosis and necrosis assay. Due to apoptosis the integrity of the cell 
membrane becomes permeable allowing YO-PRO®-1, a green-fluorescent stain, to en-
ter the cells. Hence YO-PRO®-1 can bind to the nuclear DNA, enabling the identification 
of apoptotic cells (Gawlitta et al., 2005; Fujisawa et al., 2014).  
In contrast to apoptosis, necrosis is associated with the ultimate breakdown of the 
plasma membrane. The rupture permits propidium iodide, a membrane impermeable 
and red-fluorescent intercalating agent, to bind to the DNA, identifying necrotic cells 
by red colour (Gawlitta et al., 2005; BioLegend Inc., 2019). 
Living cells are neither stained with YO-PRO®-1 nor with propidium iodide. Thus, to 
calculate the rate of apoptotic and necrotic cells after treatment the nuclei of all cells 
were counterstained with Hoechst 33342 dye, representing the total amount of cells in 
a sample (Merck, Sigma-Aldrich, 2019).  
The BT4Ca cells were seeded as described above (see. 3.2) and incubated for 48 h with 
5-FUrd and the five derivatives, which have shown the most effective cytotox-
ic/cytostatic results in the viability assay (5-FUrd, S.18, S.19, S.38, S.98 and S.101; 1 µM 
Camptothecin served as a positive control). To differentiate between apoptotic and 
necrotic processes the cells were stained with YO-PRO®-1 (1 µM), Propidium iodine (3 
µM) and Hoechst 33342 (5.4 µM) for 10 min. Photos were taken (magnification 100x) 
using an inverted epiflourescence microscope Zeiss Axiovert 135 equipped with a X–Y 
motorized stage and AxioVision 4 Modul Mark & Find 2 software (Carl Zeiss GmbH) and 
a digital AxioCam MRc camera with the AxioVision Rel. 4.8 software (Carl Zeiss GmbH). 
The total number of apoptotic and necrotic cells were determined by manual and au-
tomatic counting using Image J 1.46r software (National Institute of Health). 
Moreover, an additional second evaluation method was used to measure the percent-
age of apoptotic and necrotic cells. For this purpose the total fluorescence of all three 
dyes were recorded via the Cytation3 image reader at 490 nm excitation/530 nm emis-
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sion for YO-PRO®-1, 535 nm excitation/617 nm emission for propidium iodide and 
350nm excitation /462 nm emission for Hoechst 33342. Hence the background (blank) 
was measured at the three wavelength conditions as described previously. The back-
ground was subtracted and the cell amount compared to the negative control as well 
as the fluorescence ratios of YO-PRO®-1 /Hoechst and propidium iodide /Hoechst were 
calculated. DMSO was used as control for the dissolver and camptothecin was used as 
positive control for apoptosis. The assay was repeated four times.  
Both data, the fluorescence measurement (Fig.24-47) and the fluorescent images (see 
supplements page 150-163, Fig. 27-39), were analyzed independently.  
The Hoechst fluorescence was calculated in % of the negative control (= 100 %) and 
the significances are given compared to the DMSO control as well as to 5-FUrd and 
camptothecin. The fluorescence intensity of YO-PRO®-1 or PI is divided by the cell 
amount (Hoechst 33342 nuclei) and the mean rate of fluorescence ratio ± SEM are 
illustrated in the graphics; the significances are given compared to the DMSO control 
as well as to 5-FUrd and camptothecin. 
3.3.2. Active caspase 3 activity assay 
For the determination of activated caspases 3 and 7 the CellEvent™ Caspase-3/7 Green 
Detection Reagent was used. The reagent is a novel fluorogenic substrate consisting of 
four amino acid peptide (DEVD) conjugated to a nucleic acid binding dye. DEVD pep-
tide inhibits the ability of the dye to bind to DNA so the cell-permeant substrate is in-
trinsically non-fluorescent. After activation of caspase-3 or caspase-7 in apoptotic cells, 
the DEVD peptide is cleaved, enabling the dye to bind to DNA and produce a bright, 
fluorogenic response with absorption/emission maxima of ~502 nm/530 nm respec-
tively (ThermoFisherScientific, 2019).  
The BT4Ca cells were seeded as described above (see. 3.2) on a black Lumox® 96-
multiwell plate. After attachment (24 h), the cells were treated with 5-FUrd and the 
five most effective derivatives (S.18, 19, 38, 98 and 101; at the concentration of 12.5, 
25 and 50 µM. The proapoptotic camptothecin (1 µM) was used as positive control. 
Directly after the treatment the CellEventTM caspase-3/7 green detection reagent was 
added at a concentration of 2.5 µM. Caspase 3/7 activity was measured after 0 h, 24 h 
and 48 h of treatment. The fluorescence intensity was measured at 502 nm excita-
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tion/530 nm emission with the Cytation™ 3 image microplate reader. At the end of the 
treatment (48 h) the cells were additionally counterstained with Hoechst 33342 (5.4 
µM) without exchanging the medium. The fluorescence was detected at 350 nm exci-
tation/462 nm emission. The fluorescence of DEVD was measured in four replicates 
and the mean of the blank was subtracted. Then the percentage of the active caspase 
3 compared to the negative control (= 100%) was calculated and the mean values were 
determined. The assay was at least repeated five times.  
Therefor the CellEvent™ Caspase-3/7 Green Detection assay was used. This method is 
based on the cleavage of DEVD by the active caspase 3, causing a fluorescent signal, 
which can be detected with an emission maximum of 530nm after excitation by 502 
nm.  
3.4. Oxidative stress 
3.4.1. Reactive oxygen species (ROS) Detection 
Reactive oxygen species (ROS) may lead to oxidative stress, when an intracellular im-
balance between oxidative and anti- oxidative systems occurs (Newsholme et al., 
2016).  
To analyze the production of ROS the cells were loaded with the cell-permeant reagent 
2’,7’ –dichlorofluorescin diacetate (DCFDA). After the diffusion of DCFDA into the cells, 
it gets oxidized by ROS into 2’, 7’ –dichlorofluorescein (DCF), which is a highly fluores-
cent compound. Hence DCF can be detected by fluorescence spectroscopy with maxi-
mum excitation and emission spectra of 495 nm / 529 nm (Figueroa et al., 2018). 
The BT4Ca cells were seeded as described above (see. 3.2) and cultured for 24 h. The 
following steps were performed using only medium (DMEM high Glucose) without 
phenol red. After washing with medium alone the cells were incubated (45 min) with 
25 µM DCFDA reagent. Next the cells were treated (48 h) with 5-FUrd or the five deriv-
atives, S.18, S.19, S.38, S.98 and S.101, as well as H2O2 served as a positive control). 
During the treatment the fluorescence was measured at 485/ 535 nm with Cytation3 
multi-mode reader at several time points (30 min, 1, 2, 3, 4, 5, 24 and 48 h). At the end 
the viability of the cells was measured by PrestoBlue® assay. The amount of ROS was 
measured in four replicates and the mean of the blank was subtracted. The assay was 
repeated at least five times.  
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Figure 8: The canonical pathway. 
Ligand binding to a receptor leads to the recruit-
ment and activation of an IKK complex compris-
ing IKK alpha and/or IKK beta catalytic subunits 
and two molecules of NEMO. The IKK complex 
then phosphorylates IκB leading to degradation 
by the proteasome. NFκB then translocate to the 
nucleus to activate target genes (Abcam, 2019b 
[modified]). 
3.5. Activation of the transcription factor nuclear factor κappa B 
The nuclear factor kappa light chain en-
hancer of activated B cells (NFκB) is ex-
pressed in nearly all mammalian cells and 
is of prime importance for the regulation 
of the immune response, cell prolifera-
tion as well as cell death. p65, also 
known as RelA, is one of the five compo-
nents that form this transcription factor 
complex. Under physiological/normal 
conditions, the p50/p65 heterodimer is 
selectively bound to IκBα or IκBβ. Hence 
the NFκB subunits are localized in the 
cytoplasm due to the binding of the in-
hibitors of the IκB family, preventing the 
nuclear translocation of p50/p65. After 
stressful stimuli the IκB kinase complex gets activated inducing the disassociation of 
IκBα. The p50/p65 heterodimer is able to translocate to the nucleus and bind to specif-
ic gene promoters to modulate the expression amongst others, of pro- and anti-
inflammatory proteins (Fig. 8). Furthermore, the expression of IκBα and IκBβ are also 
up-regulated by the NFκB heterodimers in order to terminate the signaling pathway, 
functioning as a negative feedback loop (Moynagh, 2015). 
3.5.1. NFκB p65 staining  
The BT4Ca cells were seeded as described before (see. 3.2) on a 96-lumox multiwell 
plate and incubated for 48h with 5-FUrd and the 5 most effective derivatives (5-FUrd, 
S.18, S.19, S.38, S.98 and S.101). After the treatment the cells were washed with PBS 
and fixed with ice-cold methanol for 10min at 4°C. After removing the methanol and 
washing with PBS the cells were incubated with PBS containing 0.1 % Triton x100 for 
15 min. The cells were then washed again with PBS and blocked for 30 min. with 2 % 
goat serum in PBS. Afterwards, the cells were incubated with the polyclonal goat anti-
NFκB antibody (1:50 in PBS) at 4 °C overnight. The next day, the cells were washed 
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with in PBS containing 0.1 % Triton x100. Subsequently the secondary antibody (anti 
goat -Cy3 -conjugated, 1: 100 in PBS) and DAPI (1:1000 in PBS) were added for 1 h at 
room temperature. Thereafter, the cells were washed again with PBS containing 0.1 % 
Triton x100 and covered with PBS. 24 h later microscopic pictures were taken with the 
confocal laser scanning microscope Nikon Eclipse Ti. The pictures were taken at a mag-
nification of 200x and 400x and qualitative analysis was done. 
3.6. Migration 
3.6.1. Scratch assay 
Because migration and invasion play a significant role in GBM progression/metastasis, 
too, we tried to verify if the migration behavior of the cells is influenced by the treat-
ment with the most effective derivatives (5-FUrd, S.18, S.19, S.38, S.98 and S.101). 
Therefore, a wound healing assay (“Scratch assay”) was performed.  
The BT4Ca cells were seeded in a density of 3x105 cells/well as described before (see. 
3.2) on a 12 multiwell plate. The cells were cultured for 24 h, obtaining a 90 % – 100 % 
confluent monolayer, afterwards “wounds” were made with a 10 µl pipette tip in the 
middle of each well. Thereafter the cells were washed five times with PBS to remove 
detached cells. Afterwards the cells were treated with the derivatives and incubated 
for 24 h. The “wound” was photographed at the identical X-, Y-coordinate in each well 
(magnification 100x) at time 0 and every 3 hours (0, 3, 6 or 9 h), using an 
epiflourescence microscope Zeiss Axiovert 135 equipped with a X–Y motorized stage 
and AxioVision 4 Modul Mark & Find 2 software (Carl Zeiss GmbH) and a digital Axio-
Cam MRc camera with the AxioVision Rel. 4.8 software (Carl Zeiss GmbH). Effects on 
migration were plotted as a percentage of wound closure (% of wound closure = [(Δt) × 
100 %]/At 0 h; where “At 0 h” is the area of wound measured immediately after 
scratching, “At 3, 6 or 9 h” indicates the area of wound measured 3, 6 or 9 h after 
scratching and Δt= At 0 h – At 3, 6 or 9 h (Yue et al., 2010). 
The assay was repeated three times and the size of the wound area was measured and 
calculated in % of the area at time point 0h.  
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3.6.2. Light microscopy 
At the end of the incubation (48 h) with 5-FUrd or the derivatives, the morphological 
integrity of the cells was controlled by microscopy. Light microscopy photos of the cells 
treated with 12.5, 25 and 50 µM of 5-FUrd or the derivatives, as well as the negative 
and the DMSO control were taken by AxioCam MRm Camera using phase contrast ap-
proach.  
3.7. Biochemistry 
3.7.1. Protein extraction  
After culture the medium was collected and the adherent cells were washed with 1 ml 
ice-cold DPBS. DPBS together with the supernatant was centrifuged for 10 min at 250 x 
g to collect the non-adherent cells, whereas the supernatant was discarded.  
Meanwhile the adherent cells were scratched off, diluted with pure medium (without 
FBS) and transferred to a low-binding tube. The cell pellet, which was gained from the 
culture medium before, was added to the harvested cells. After centrifugation (10 min 
250x G) the complete cell pellet (non-adherent and adherent cells) was washed with 
pure medium (without FBS) to remove the remaining FBS. For the GSH-GSSG assay 400 
µl 2.5% sulfosalicylic acid (SSA) were added to the cell pellet, for the PCNA ELISA the 
pellet was resuspended in 400 µl RIPA+ (Radio-Immunoprecipitation Assay mixed with 
protease inhibitor cocktail) lysis buffer pH 7.5. After centrifugation (10 min at 13,000 x 
G at 4°C) to remove the cellular debris, the protein concentration in the supernatant 
was determined by BCA assay.  
3.7.2. Protein quantification, BCA assay 
The bicinchoninic acid assay (BCA) is a spectrophotometric analytical method to meas-
ure the concentration of proteins in a solution. Cu2+ is reduced by protein in an alkaline 
medium to Cu1+. Following, the so arisen cuprous cation (Cu1+) can be detected by bi-
cinchoninic acid, which induces a colorimetric switch. Therefore, the proteins are 
transferred into an alkaline environment, where the peptide bonds react with copper 
to a light blue complex (~biuret reaction). Then the bicinchoninic acid binds to the 
emerging, reduced Cu1+ cations, which can be observed as an intense purple-colored 
reaction. The complex of BCA and Cu1+ cations exhibit a strong linear absorbance with 
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increasing protein concentration, which can be measured at 562 nm (Thermo Fisher 
Scientific, 2019).  
For protein quantification the absorbance of bovine serum albumin (BSA) standard, as 
well as the samples were measured in duplicates on a 96-well plate. After adding the 
BCA reagent, the plate was incubated for 30 min in the dark. The absorbance at 562 
nm was measured with a Microplate reader and a standard curve (0, 25, 125, 250, 500, 
750, 1000, 1500 and 2000 mg/ml) was generated. Thereafter, the protein concentra-
tion of the samples was calculated by linear interpolation using the standard curve 
(Fig.9). 
  
Figure 9: BCA standard curve.  
Representative example of a standard curve, generated by the measurement and use of the protein 
standards (0, 25, 125, 250, 500, 750, 1000, 1500 and 2000 µg/ml). The formula of the curve can be used 
to calculate the protein concentration of (unknown) samples. 
The measurements were performed in four replicates and the mean of the blank was 
subtracted. The assay was repeated three times and calculated in µg/ml. 
3.7.3. GSH/GSSG Assay 
BT4Ca cells were seeded, cultured, treated and collected as described above (see 
3.8.1). To measure the amount of total glutathione (tGSH) and oxidized (GSSG) form, a 
glutathione assay was performed according to Tietze (Tietze, 1969) based on the de-
termination of total GSH (GSH + GSSG) in the absence of 2-vinylpyridine (thiol scaven-
ger) and GSSG, determined with use of 2-vinylpyridine, in presence of the enzyme glu-
tathione reductase (GR).  
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For the determination of the total glutathione (tGSH) 30 µl of the sample or tGSH 
standards (0, 0.025, 0.05, 0.1 and 0.25 nmol/ml) were mixed with 288 µl tri-
ethanolamine (TEA/SSA) (solution 1). Following, 100 µl of solution 1, were added to 
500 µl glutathione buffer and 200 µl 5,5-dithio-bis-2-nitrobenzoic acid (DTNB, contain-
ing 2.5units GR), mixed in a plastic cuvette (semi-micro) and first measured after 6 min 
at 412 nm with a photometer, this value is taken as tGSH time 0 (T0).  
For the measurement of the oxidized glutathione (GSSG), 200 µl of sample or GSSG 
standards (0, 0.025, 0.05, 0.1 and 0.25 nmol/ml) were incubated at room temperature 
for 30 min with 4 µl 2-vinylpyridine. By adding 12 µl TEA  the reaction was stopped 
(solution 2) and 100µl of solution 2 were mixed with 500 µl glutathione buffer and 200 
µl DTNB (containing 2.5units GR) in a plastic cuvette. Then after 6 min the samples 
were measured at 412 nm with a photometer (T0). 
The reaction (tGSH or GSSG) was started after the first measurement (T0) by addition 
of 200µl NADPH and 6 min later the samples were measured again at 412 nm (T6). 
After the subtraction of the mean of the blank (Blank = 0 nmol/ml) the difference of 
the absorbance between T0 and T6 was calculated. All measurements were performed 
in duplicates. The assay was repeated three times and calculated in % of the negative 
control. The concentration of tGSH or GSSG of the samples were calculated by linear 
interpolation using the respective standard curve (Fig.10).  
 
Figure 10: GSH and GSSG standard curves.  
Representative example of a GSH (A) and GSSG (B) standard curves generated by the measurement and 
use of the standards (0, 0.025, 0.05, 0.1 and 0.25 nmol/ml). The formula of the curves can be used to 
calculate the GSH or GSSG concentration of (unknown) samples. 
 The amount of tGSH and GSSH in the samples was normalized with the respective pro-
tein amount determined by BCA. Reduced (r)GSH was computed by subtraction 
(rGSH=tGSH-GSSG).  
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3.7.4. PCNA ELISA 
The assay was performed according to manufacturer’s instructions of the CytoSelect 
Proliferating Cell Nuclear Antigen (PCNA) ELISA Kit from Bio Celllabs (Cell Biolabs, Inc., 
2019). 
The BT4Ca cells were seeded, cultured, treated and collected as described above (see 
3.8.1). For the quantification of the PCNA fraction, duplicates of the standard as well as 
60 ng protein of the samples were loaded on the pre-coated 96 plates with capture 
antibody and incubated for 24 h at 4°C on an orbital shaker (100 rpm/min). After three 
times washing with washing buffer the primary PCNA antibody, diluted 1:1000 with 
diluent reagent, was added and incubated for 1h at RT on an orbital shaker (100 
rpm/min). After another three washing steps, the HRP-conjugated secondary antibody 
(1:1000) was added. Afterwards the unbound antibody was removed by washing with 
washing buffer and 100 µl HRP-substrate TMB (3,3´,5,5´-tetramethylbenzidine) were 
added. After 30 min 100 µL of the stop solution (2N H2SO4) were added and the ab-
sorbance was measured at 450 nm. By generating a standard curve (0, 6.25, 12.5, 25, 
50, 100, 200 and 400 ng/ml), the amount of PCNA was calculated by linear interpola-
tion (Fig. 11). 
 
Figure 11: CytoSelect™ Proliferating Cell Nuclear Antigen (PCNA) Standard Curve. 
Representative example of a standard curve generated by the measurement and use of the PCNA-
standard (0, 6.25, 12.5, 25, 50, 100, 200 and 400 ng/ml). The formula of the curve can be used to calcu-
late the PNCA concentration of (unknown) samples. 
The amount of PCNA was measured in four replicates and the mean of the blank was 
subtracted. The assay was repeated three times and calculated in % of the negative 
control.  
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3.8. Evaluation and statistics  
At the end of every assay the mean values of all experiments were calculated with Ex-
cel2010. Additionally, the standard deviation (SEM) and the significance versus DMSO, 
camptothecin and 5-FUrd were calculated. For all experiments SigmaPlot®12 software 
was used to carry-out statistical analyses. Results are presented as means ± standard 
error of the mean (SEM). After testing for normality (by Shapiro–Wilk), the unpaired 
Student’s t-test or Mann–Whitney U-test were used, whereby a P value of < 0.05 was 
chosen as failure criterion. *p < 0.05, **p<0.01 and ***p<0.001 considered to be sta-
tistically significant vs DMSO; #p < 0.05, ##p<0.01 and ###p<0.001 statistically significant 
vs. 5-FUrd; °p < 0.05, °°p<0.01 and °°°p<0.001 statistically significant vs. camptothe-
cin. Results were plotted by the use of Microsoft Excel. 
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4. Results 
4.1. Effects of the novel derivatives on cell morphology  
After the treatment of the different cell lines with the novelly synthesized derivatives, 
morphological alterations and changes of the cell density were controlled by light mi-
croscopy and photographically documented (magnification 100x). Thereby a first im-
pression of the impact of the novel derivatives on the cells was gained. The photos of 
the cells treated with 5-FUrd and the five most effective derivatives (S.18, 19, 38, 98 
and 101) at the concentrations of 12.5, 25 and 50 µM can be found in the supplements 
page 126-146, Fig. 1-21. These pictures illustrate an explicit reduction of the cell densi-
ty and a destruction of the cell morphology depending on the added derivative and its 
concentration as well as the specific cell line.   
4.2. Effects of the novel derivatives on the cell viability  
To identify nucleolipids with any cytotoxic or cytostatic effects, all 120 derivatives were 
tested by using the PrestoBlue™ cell viability assay. The viability of the rat BT4Ca, hu-
man GOS3 glioma cells as well as PMA differentiated macrophages (THP1) was meas-
ured after an incubation of 48 h with the derivatives under test at concentrations of 
1.56-50 µM. Following, the effects of the five most interesting derivatives (S.18, 19, 38, 
98 and 101) on the viability of rat BT4Ca and human GOS3 glioma cells are shown (Fig. 
12 and 13).  
All derivatives were solubilized in DMSO; hence a DMSO control was performed using 
medium with 0.25 % DMSO, corresponding to the concentration of DMSO in 50 µM 
maximal working concentration of the derivatives under test. No significant cytotoxic 
effect of 0.25 % DMSO control on the viability of any cell type under test was ob-
served, compared to the negative control (incubation with medium alone; = 100 % 
viability) (Fig. 12-17). The viability is calculated in % of the negative control (= 100% 
viability) and the significances are given compared to the 0.25 % DMSO control as well 
as to 5-FUrd. 
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After the incubation (48 h) of the rat BT4Ca glioma cells with 5-FUrd (1.56-50 µM) a 
significant (p<0.001) cytostatic effect with a reduction of the viability by ca. -75.0 % to -
85.0 % was detected compared to the negative control (= 100 % viability) (Fig.12).   
The treatment of the rat BT4Ca glioma cells with derivative S.18 at the concentrations 
of 25 and 50 µM resulted in a significant reduction of the viability by -58.6 % (p<0.01) 
and -81.8 % (p<0.001) compared to the negative control (Fig.12).   
The incubation with derivative S.19 showed a significant decrease of the viability of rat 
BT4Ca glioma cells by -20.4 % (6.25 µM, p<0.01), -33.3 % (12.5 µM, p<0.01), -100.0 % 
(25 µM, p<0.001) and -100 % (50 µM, p<0.001) compared to the negative control. In 
comparison to 5-FUrd, the treatment with S.19 significantly (p<0.05) reduced the via-
bility of rat BT4Ca glioma cells by -18.5 % (25 µM) and -15.4 % (50µM) (Fig. 12).   
The incubation of the rat BT4Ca glioma cells with derivative S.38 resulted in a signifi-
cant (p<0.001) decrease of the viability by -21.2% (12.5 µM), -70.0 % (25 µM) and -95.9 
% (50µM) compared to the negative control (Fig.12).   
The treatment with derivative S.98 led to a significant inhibition of the viability of rat 
BT4Ca glioma cells by -37.9 % (1.56 µM, p<0.01), -65.1% (3.12 µM, p<0.01), -80.3 % 
(6.25 µM, p<0.01), -87.5 % (12.5 µM, p<0.001), -92.4 % (25 µM, p<0.001), -95.1 % (50 
µM, p<0.01) compared to the negative control (Fig.12).   
The incubation of the rat BT4Ca glioma cells with derivative S.101 (12.5, 25 or 50 µM) 
revealed a significant reduction by -43.2 % (p<0.01), - 58.6 % (p<0.001) and -74.9 % 
(p<0.001) compared to the negative control (Fig.12).   
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Figure 12: Viability (in %) of rat BT4Ca glioma cells after treatment (48h). 
Viability (in % of the negative control) of rat BT4Ca glioma cells after 48 h incubation with 5-FUrd (posi-
tive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by PrestoBlue® assay. Values 
are given (in % viability of control [incubation with medium alone; = 100 % viability]) as mean ± SEM; 
***p<0.001, significance vs. 0.25 %DMSO control; #p<0.05 significance vs. 5-FUrd at equal concentra-
tion; n=5-50 independent experiments assayed in quadruplicates. 
The treatment of the human GOS3 glioma cells with 5-FUrd (1.56-50µM) also resulted 
in a significant (p<0.001) cytostatic effect with an inhibition of the viability by ca. -20 to 
-35 % compared to the negative control (Fig.13) 
The incubation of the human GOS3 glioma cells with derivative S.18 revealed at the 
concentrations 25 and 50 µM a significant inhibition of the cell-viability by -28.1 % 
(p<0.04) and -91.2 % (p<0.001) compared to the negative control. In comparison to 5-
FUrd, the treatment with S.18 significantly (p<0.01) reduced the viability of the human 
GOS3 glioma cells by -60.3 % (50µM) (Fig.13). 
After the incubation of the human GOS3 glioma cells with S.19 (25 and 50 µM) the 
viability of the cells was abolished, so compared to the negative control not any viable 
cells could be detected. In comparison to 5-FUrd, the treatment with S.19 significantly 
inhibited the viability of the human GOS3 glioma cells by  -66.1 % (25 µM, p<0.001) 
and -69.1 % (50µM, p<0.01) (Fig. 13).   
The incubation with derivative S.38 significantly (p<0.01) diminished the viability of the 
human GOS3 glioma cells by -13.0 % (25µM) and -85.9 % (50µM) compared to the 
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negative control.  In comparison to 5-FUrd, the treatment with S.38 significantly inhib-
ited the viability of the human GOS3 glioma cells only at the concentration of 50 µM by 
-55.0 % (p<0.01) (Fig. 13).   
After the treatment of the human GOS3 glioma cells with S.98 the viability was signifi-
cantly reduced by -26.0 % (6.25 µM, p<0.01), -61.5 % (12.5 µM, p<0.01), -97.0% (25 
µM, p<0.001), -100.0 % (50 µM, p<0.001) compared to the negative control. In com-
parison to 5-FUrd the incubation with S.98 significantly diminished the viability of the 
human GOS3 glioma cells at the concentrations 12.5, 25 and 50 µM by -37.0 % 
(p<0.001), -63.0 % (p<0.001) and -70.4 % (p<0.01), respectively (Fig. 13).   
The treatment with derivative S.101 significantly inhibited the viability of the human 
GOS3 glioma cells by -15.8 % (12.5 µM, p<0.05), -42.2 % (25 µM, p<0.001) and -79.2 % 
(50 µM, p<0.001) compared to the negative control. In comparison to 5-FUrd, the in-
cubation with S.101 significantly diminished the viability of the human GOS3 glioma 
cells only at the concentration of 50 µM by -48.3 % (p<0.01) (Fig. 13).   
 
Figure 13: Viability (in %) of human GOS3 glioma cells after treatment (48h). 
Viability (in % of the negative control) of human GOS3 glioma cells after 48 h incubation with 5-FUrd 
(positive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by PrestoBlue® assay. 
Values are given (in % viability of control [incubation with medium alone; = 100 % viability]) as mean ± 
SEM; *p<0.05, **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; 
##
p<0.01, 
###
p<0.001, signif-
icance vs. 5-FUrd at equal concentration; n=5-50 independent experiments assayed in quadruplicates. 
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Moreover, these five nucleolipids were additionally tested on four further human gli-
oma cell lines (G28, G112, U251 and U87) to examine if the derivatives are also effec-
tive against other human glioma cell lines with different characteristics and properties 
(Fig. 14-17).  
Incubation of the human G28 glioma cells with 5-FUrd revealed a cytotoxic effect and 
led at the concentrations of 12.5, 25 and 50 µM to a significant (p<0.001) decrease by -
12.8 %, -23.1 % and -35.2% compared to the negative control (Fig.14). 
The treatment with derivative S.18 significantly decreased the viability of the human 
G28 glioma cells at the concentrations of 25 and 50µM by -6.9 % (p<0.05) and -100 % 
(p<0.001) compared to the negative control. In comparison to 5-FUrd, the incubation 
with S.18 (50µM) significantly (p<0.001) reduced the viability of the human G28 glioma 
cells by -67.6 % (Fig. 14). 
Moreover, the viability of the human G28 glioma cells was significantly (p<0.001) di-
minished through treatment with derivative S.19 by -17.1 % (6.25 µM), -84.5 % (12.5 
µM), -99.7 % (25 µM) and -98.7 % (50 µM) compared to the negative control. In com-
parison to 5-FUrd, the incubation with S.19 significantly decreased the viability of the 
human G28 glioma cells at the same concentrations by -18.1 % (6.25 µM, p<0.01), -
71.7 % (12.5 µM, p<0.001), -76.6 % (25 µM, p<0.001) and -63.5 % (50 µM, p<0.001) 
(Fig. 14).   
After the incubation of the human G28 glioma cells with S.38 the viability was signifi-
cantly reduced by -3.8 % (6.25µM, p<0.05), -1.7 % (12.5µM, p<0.01), -16.5 % (25µM, 
p<0.01) and -97.5 % (60 µM, p<0.001) compared to the negative control. In compari-
son to 5-FUrd, the treatment with S.38 significantly decreased the viability of the hu-
man G28 glioma cells only at the concentration of 50 µM by -62.2 % (p<0.001) (Fig. 14).   
After the incubation with S.98 (1.56, 3.12, 6.25, 12.5, 25 or 50 µM) the viability of hu-
man G28 glioma cells was significantly decreased by -6.0 % (p<0.05), -11.7 % (p<0.001), 
-47.4 % (p<0.001), -72.9 % (p<0.001), -100 % (p<0.001) and -98.2 % (p<0.001), respec-
tively, compared to the negative control. In comparison to 5-FUrd, the treatment with 
S.98 significantly reduced the viability of the human G28 glioma cells at the same con-
centrations by -14.3 % (1.56 µM, p<0.05), -22.7 % (3.12 µM, p<0.01), -48.4 % (6.25 µM, 
p<0.001), -72.9 % (12.5 µM p<0.001), -77.3 % (25 µM, p<0.001) and -63.0 % (50 µM, 
p<0.001) (Fig. 14).   
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The incubation of the human G28 glioma cells with derivative S.101 resulted in a signif-
icant (p<0.001) inhibition of the viability by -5.9 % (6.25 µM), -22.3 % (12.5 µM), -43.4 
% (25 µM) and -65.8 % (50 µM) compared to the negative control. In comparison to 5-
FUrd, the treatment with S.101 significantly reduced the viability of the human G28 
glioma cells at the concentrations of 12.5, 25 and 50 µM by -9.5 % (p<0.01), -20.3 % 
(p<0.001) and -30.6 % (p<0.001) (Fig. 14).   
 
 
Figure 14: Viability (in %) of human G28 glioma cells after treatment (48h). 
Viability (in % of the negative control) of human G28 glioma cells after 48 h incubation with 5-FUrd (pos-
itive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by PrestoBlue® assay. Values 
are given (in % viability of control [incubation with medium alone; = 100 % viability]) as mean ± SEM; 
*p<0.05, **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; 
#
p<0.05, 
##
p<0.01, 
###
p<0.001, 
significance vs. 5-FUrd at equal concentration; n=5 independent experiments assayed in quadruplicates. 
 
After treatment of the human G112 glioma cells with 5-FUrd (12.5, 25 and 50µM) the 
viability was significantly (p<0.001) lowered by -17.0 %, -26.8 % and -39.3 % compared 
to the negative control (Fig. 15). 
The incubation with derivative S.18 significantly reduced the viability of the human 
G112 glioma cells by -91.2 % (50 µM) compared to the negative control. In comparison 
to 5-FUrd, the treatment with S.18 significantly (p<0.001) decreased the viability of the 
human G112 glioma cells by -51.9 % (50µM) (Fig. 15).   
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The incubation of the human G112 glioma cells with S.19 (6.25, 12.5, 25 and 50µM) 
resulted in a significant reduction of the viability by -14.3 % (p<0.01), -71.2 % 
(p<0.001), -86.2 % (p<0.001) and -86.0 % (p<0.001) compared to the negative control. 
In comparison to 5-FUrd, the treatment with S.19 significantly (p<0.001) inhibited the 
viability of the human G112 glioma cells by -54.2 % (12.5 µM,), -59.4 % (25 µM) and -
46.6 % (50 µM) (Fig. 15).   
After the treatment with derivative S.38 the viability of the human G112 glioma cells 
was significantly diminished by -3.3 % (6.25 µM, p<0.01), -8.2 % (12.5 µM, p<0.001), -
45.2 % (25 µM, p<0.001) and -88.2 % (50 µM, p<0.001) compared to the negative con-
trol. In comparison to 5-FUrd, the incubation with S.38 significantly decreased the via-
bility of the human G112 glioma cells only at the concentration of 50 µM by -48.9 % 
(p<0.001) (Fig. 15).   
The treatment with derivative S.98 showed at the concentrations of 3.12, 6.25, 12.5, 
25 or 50 µM a significant inhibition of the viability of the human G112 glioma cells by -
37.4 % (p<0.01), -49.7 % (p<0.01), -60.6 % (p<0.001), -87.1 % (p<0.001) and -87.5 % 
(p<0.001), respectively, compared to the negative control. In comparison to 5-FUrd, 
the incubation with S.98 significantly (p<0.001) decreased the viability of the human 
G112 glioma cells at the same concentrations by -47.8 % (3.12 µM), -45.5 % (6.25 µM), 
-43.6 % (12.5 µM), -60.3 % (25 µM) and -48.1 % (50 µM) (Fig. 15).   
The incubation of the human G112 glioma cells with S.101 (6.25, 12.5, 25 or 50 µM) 
revealed a significant inhibition of the viability by -10.5 % (p<0.01), -36.6. % (p<0.001), 
-43.7 % (p<0.001) and -53.3 % (p<0.001) compared to the negative control. In compari-
son to 5-FUrd, the treatment with S.101 significantly reduced the viability of the hu-
man G112 glioma cells only at the concentrations of 12.5 and 25 µM by -19.6 % 
(p<0.05) and -16.9 % (p<0.05) (Fig. 15).   
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Figure 15: Viability (in %) of human G112 glioma cells after treatment (48h). 
Viability (in % of the negative control) of human G112 glioma cells after 48 h incubation with 5-FUrd 
(positive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by PrestoBlue® assay. 
Values are given (in % viability of control [incubation with medium alone; = 100 % viability]) as mean ± 
SEM; **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; 
###
p<0.001 significance vs. 5-FUrd at 
equal concentration; n=5 independent experiments assayed in quadruplicates. 
After the treatment with 5-FUrd the viability of the human U251 glioma cells was sig-
nificantly (p<0.001) reduced by -54.6 % (12.5 µM), -73.8 % (25 µM) and -82.0 % (50 
µM) compared to the negative control (Fig.16). 
The incubation of the human U251 glioma cells with S.18 (25 and 50 µM) revealed a 
significant (p<0.001) inhibition of the viability by -86.4 % and -98.3 % compared to the 
negative control. In comparison to 5-FUrd, the treatment with S.18 (50µM) significant-
ly reduced the viability of the human U251 glioma cells (p<0.05) by -16.3 % (Fig. 16).   
Incubation with derivative S.19 significantly (p<0.001) decreased the viability of the 
human U251 glioma cells by -86.2 % (12.5 µM), - 90.5 % (25 µM) and -91.4 % (50 µM) 
compared to the negative control. In comparison to 5-FUrd, the treatment with S.19 
significantly inhibited the viability of the human U251 glioma cells at the concentra-
tions of 12.5 and 25 µM by -31.6 % (p<0.01) and -16.8 % (p<0.05) (Fig. 16).   
The incubation of the human U251 glioma cells with S.38 (3.12, 6.25, 12.5, 25 or 50 
µM) revealed a significant reduction of the viability by -20.5 % (p<0.05), -40.9 % 
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(p<0.001), -43.9 % (p<0.001), -76.1 % (p<0.001) and -93.2 % (p<0.001) compared to the 
negative control (Fig.16).   
After the treatment of the human U251 glioma cells with S.98 (1.56, 3.12, 6.25, 12.5, 
25 or 50 µM) the viability was significantly reduced by -43.0 % (p<0.01), -49.3 % 
(p<0.01), -49.5 % (p<0.001), -70.5 % (p<0.01) -94.7 % (p<0.001)  and -95.7 % (p<0.001), 
respectively, compared to the negative control. In comparison to 5-FUrd, the incuba-
tion with S.98 significantly diminished the viability of the human U251 glioma cells only 
at the concentration of 25 µM by -21.0 % (p<0.05) (Fig. 16). 
Furthermore, after the treatment with derivative S.101 the viability of the human 
U251 glioma cells was significantly diminished by -40.3 % (6.25 µM, p<0.01), -38.4 % 
(12.5 µM, p<0.01), -41.5 % (25 µM, p<0.001) and -64.3 % (50 µM, p<0.01) compared to 
the negative control (Fig.16).   
 
 
Figure 16: Viability (in %) of human U251 glioma cells after treatment (48h). 
Viability (in % of the negative control) of human U251 glioma cells after 48 h incubation with 5-FUrd 
(positive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by PrestoBlue® assay. 
Values are given (in % viability of control [incubation with medium alone; = 100 % viability]) as mean ± 
SEM; *p<0.05, **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; 
#
p<0.05, 
##
p<0.01 signifi-
cance vs. 5-FUrd at equal concentration; n=5 independent experiments assayed in quadruplicates. 
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The incubation of the human U87 glioma cells with 5-FUrd revealed at all concentra-
tions a significant (p<0.001) inhibition of the viability by -26.2 % (1.56 µM), -37.8 % 
(3.12 µM), 40.8 % (6.25 µM), 49.1 % (12.5 µM), -61.6 % (25 µM) and -66.0 % (50 µM) 
compared to the negative control (Fig.17). 
The treatment of the human U87 glioma cells with S.18 led only at the concentrations 
of 25 and 50 µM to a significant reduction by -51.2% (p<0.001) and -85.0 % (p<0.01) in 
comparison to the negative control (Fig.17).   
After the incubation with derivative S.19 (12.5, 25 and 50 µM) the viability of the hu-
man U87 glioma cells was significantly diminished by -63.5 % (p<0.01), -83.6 % 
(p<0.001) and -85.2 % (p<0.01), respectively, compared to the negative control. In 
comparison to 5-FUrd, the treatment with S.19 significantly reduced the viability of the 
human U87 glioma cells at the concentrations 12.5 and 25 µM by -14.3 % (p<0.05) and 
-22.0 % (p<0.01) (Fig. 17).   
The human U87 glioma cells showed after the incubation with S.38 a significant de-
crease of the viability by -3.5 % (6.25 µM, p<0.05), -11.4 % (12.5 µM, p<0.001), -46.5 % 
(25 µM, p<0.001) and -88.5 % (50 µM, p<0.01) compared to the negative control. In 
comparison to 5-FUrd, the treatment with S.38 significantly diminished the viability of 
the human U87 glioma cells only at the concentration of 50 µM by -22.5 % (p<0.05) 
(Fig. 17).   
After the incubation with S.98 the human U87 glioma cells revealed a significant inhibi-
tion of the viability by -23.0 % (1.56 µM p<0.001), -39.1 % (3.12 µM, p<0.001), -51.1 % 
(6.25 µM, p<0.001), -55.3 % (12.5 µM, p<0.001), -86.2 % (25 µM, p<0.01) and -90.2 % 
(50 µM, p<0.01) compared to the negative control. In comparison to 5-FUrd, the 
treatment with S.98 significantly diminished the viability of the human U87 glioma 
cells only at the concentrations of 25 and 50 µM by -24.6 % (p<0.01) and -24.3 % 
(p<0.05), respectively (Fig. 17).   
The treatment of the human U87 glioma cells with S.101 (1.56-50 µM) led to a signifi-
cant inhibition of the viability by -0.9% (1.56 µM, p<0.001), -8.2 % (3.12 µM, p<0.001),- 
16.4 % (6.25 µM, p<0.001), -32.7 % (12.5 µM, p<0.01), -42.0 % (25 µM, p<0.001) and -
75.2 % (50µM, p<0.001) compared to the negative control (Fig.17).    
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Figure 17: Viability (in %) of human U87 glioma cells after treatment (48h).  
Viability (in % of the negative control) of human U87 glioma cells after 48 h incubation with 5-FUrd (pos-
itive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by PrestoBlue® assay. Values 
are given (in % viability of control [incubation with medium alone; = 100 % viability]) as mean ± SEM; 
*p<0.05, **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; 
#
p<0.05, 
##
p<0.01 significance vs. 
5-FUrd at equal concentration; n=5 independent experiments assayed in quadruplicates. 
 
For the verification of a broad range of activity of these derivatives, we additionally 
analyzed the effects on the viability of more human tumors cells like colon (HT29), 
hepato (HepG2), pancreas (Panc-1) and murine renal (RenCa) carcinomas cell lines. The 
results for these cell lines can be found in the supplements page 147-149, Fig. 23- 26: 
The figures show the inhibition of the viability depending on the derivative under test, 
its concentration as well as the specific cell line. Comparing the derivatives, S.19 and 
S.98 apparently bear the most inhibitive effects on the viability of these tumor cell 
lines. 
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4.3. Cytotoxicity of the novel derivatives on different glioma cell lines  
For the verification of the results documented via the viability assay, a cytotoxicity as-
say was performed. The cytotoxicity on all six glioma cell lines (rat BT4Ca, human 
GOS3, G28, G112, U251 and U87) was measured after an incubation of 48 h with the 
derivatives at concentrations of 1.56-50 µM. All derivatives were solubilized in DMSO; 
hence a DMSO control was performed using medium with 0.25 % DMSO, correspond-
ing to the concentration of DMSO in 50 µM maximal working concentration of the de-
rivatives under test. No significant cytotoxic effect of the 0.25 % DMSO control on any 
researched cell type was observed (Fig. 18-23), compared to the negative control (in-
cubation with medium alone). The cytotoxicity is calculated in % of the negative con-
trol (= 0 % cytotoxicity) and the significances are given compared to the 0.25 % DMSO 
control as well as to 5-FUrd.  
The incubation of the rat BT4Ca glioma cells with 5-FUrd significantly increased the 
cytotoxicity by +94.5 % (12.5 µM, p<0.001), +96.7 % (25 µM, p<0.001) and +97.5 % (50 
µM, p<0.01) compared to the negative control (Fig. 18). 
Treatment of the rat BT4Ca glioma cells with S.18 revealed at the concentration 25 and 
50 µM a significant (p<0.01) elevation of the cytotoxicity by +39.6 % and +98.3 % com-
pared to the negative control (Fig. 18). 
After the incubation with derivative S.19 the cytotoxicity on the rat BT4Ca glioma cells 
was significantly enhanced at the concentration 12.5, 25 and 50 µM (p<0.01) by +43.5 
%, +98.1 % and +98.5 % compared to the negative control (Fig. 18).  
The treatment of rat BT4Ca glioma cells with S.38 led to a significant elevation of the 
cytotoxicity by +36.8 % (12.5 µM, p<0.01), +83.1 % (25 µM, p<0.001) and +98.4 % (50 
µM, p<0.01) compared to the negative control (Fig. 18). 
Incubation with S.98 significantly raised the cytotoxicity on the rat BT4Ca glioma cells 
(p<0.01) by +98.5 % (12.5 µM), +98.5 % (25 µM) and +98.8 % (50 µM) compared to the 
negative control (Fig. 18). In comparison to 5-FUrd, the treatment with S.98 12.5 µM 
significantly enhanced the cytotoxicity on the rat BT4Ca glioma cells (p<0.05) by +3.9 % 
(12.5 µM) (Fig. 18). 
After the treatment of the rat BT4Ca glioma cells with S.101 the cytotoxicity was signif-
icantly elevated by +25.6 % (12.5 µM, p<0.01), +53.3 % (25 µM, p<0.01) and +92.7 % 
(50 µM, p<0.001) compared to the negative control (Fig. 18). 
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Figure 18: Cytotoxicity on rat BT4Ca glioma cells. 
Cytotoxicity (in % of the neg. control) on rat BT4Ca glioma cells after treatment (48 h) with 5-FUrd (posi-
tive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by SRB assay. Values are given 
(in % cytotoxicity of negative control [incubation with medium alone = 0 % cytotoxicity]) as mean ± SEM; 
**p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; n=5 independent experiments assayed in 
quadruplicates. 
Due to the treatment with 5-FUrd the cytotoxicity on the human GOS3 glioma cells 
was significantly (p<0.001) increased by +39.0 %, +40.4 % and +42.5 % at all three con-
centrations (12.5, 25 and 50 µM) compared to the negative control (Fig. 19). 
The incubation with S.18 showed at the concentration of 50 µM a significant raise of 
the cytotoxicity on the human GOS3 glioma cells by +62.5 % (p<0.001) compared to 
the negative control. In comparison to 5-FUrd, the treatment with S.18 50 µM led to a 
significant (p<0.001) increase of the cytotoxicity on the human GOS3 glioma cells by 
+20.1 % (Fig. 19). 
The human GOS3 glioma cells revealed after the treatment with 25 and 50 µM S.19 a 
significant rise of the cytotoxicity by +89.4 % (p<0.001) and +97.9 % (p<0.01) compared 
to the negative control. In comparison to 5-FUrd, the incubation with the same con-
centrations of derivative S.19 led to a significant increase of the cytotoxicity on the 
human GOS3 glioma cells by +49.0 % (25 µM, p<0.001) and +55.4 % (50 µM p<0.01) 
(Fig. 19). 
After the incubation with derivative S.38 12.5, 25 and 50 µM the cytotoxicity on the 
human GOS3 glioma cells was significantly enhanced by +17.8 % (p<0.001), +23.4 % 
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(p<0.001) and +96.9 % (p<0.01) compared to the negative control. In comparison to 5-
FUrd, only the treatment with S.38 50 µM significantly (p<0.01) raised the cytotoxicity 
on the human GOS3 glioma cells by +54.1 % (Fig. 19). 
Incubation with derivative S.98 revealed a significant boost of the cytotoxicity on hu-
man GOS3 glioma cells at all three concentrations (12.5, 25 and 50 µM) by +67.1 % 
(p<0.001), +99.5 % (p<0.01) and +97.8 % (p<0.01) compared to the negative control. In 
comparison to 5-FUrd, the treatment with S.98 significantly increased the cytotoxicity 
on the human GOS3 glioma cells by +28.1 % (12.5 µM, p<0.001), +59.1 % (25 µM, 
p<0.01) and +55.3 % (50 µM, p<0.01) (Fig. 19). 
The incubation of human GOS3 glioma cells with S.101 led to a significant rise of the 
cytotoxicity by +30.9 % (12.5 µM, p<0.01), +53.0 % (25 µM, p<0.001) and +70.8 % (50 
µM, p<0.001) compared to the negative control. In comparison to 5-FUrd, the treat-
ment with S.101 significantly (p<0.01) enhanced the cytotoxicity on the human GOS3 
glioma cells by +12.6 % (25 µM) and +28.3 % (50 µM) (Fig. 19). 
 
Figure 19: Cytotoxicity on human GOS3 glioma cells. 
Cytotoxicity (in % of the neg. control) on human GOS3 glioma cells after treatment (48 h) with 5-FUrd 
(positive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by SRB assay. Values are 
given (in % cytotoxicity of negative control [incubation with medium alone = 0 % cytotoxicity]) as mean ± 
SEM; **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; 
##
p<0.01, 
###
p<0.001, significance vs. 
5-FUrd at equal concentration; n=5 independent experiments assayed in quadruplicates. 
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After the treatment with 5-FUrd the human G28 glioma cells also showed a significant 
gain of the cytotoxicity by +15.9 % (12.5 µM, p<0.01), +24.9 % (25 µM, p<0.001) and 
+32.1 % (50 µM, p<0.001) compared to the negative control (Fig. 20). 
Incubation with S.18 50 µM revealed a rise of the cytotoxicity on the human G28 glio-
ma cells by +99.4 % (p<0.001) compared to the negative control. In comparison to 5-
FUrd, the treatment with S.18 50 µM significantly (p<0.001) raised the cytotoxicity on 
the human G28 glioma cells by +67.3 % (Fig. 20). 
Through the treatment with S.19 the human G28 glioma cells revealed a significant 
(p<0.001) boost of the cytotoxicity by +91.2 % (12.5 µM), +99.9 % (25 µM) and +99.5 % 
(50 µM) compared to the negative control. In comparison to 5-FUrd, the incubation 
with S.19 (12.5, 25 and 50µM) significantly (p<0.001) enhanced the cytotoxicity on the 
human G28 glioma cells by +75.3 %, +75.0 % and +67.4 % (Fig. 20). 
The human G28 glioma cells showed after the treatment with S.38 (25 and 50 µM) a 
significant (p<0.001) enhanced cytotoxicity by +82.8 % and +99.4 % compared to the 
negative control. In comparison to 5-FUrd, the incubation with S.38 led at the same 
concentrations to a significant (p<0.001) increase of the cytotoxicity on the human G28 
glioma cells by +58.0 % (25 µM) and +67.2 % (50 µM) (Fig. 20). 
After incubation with S.98, the human G28 glioma cells revealed a significant (p<0.001) 
elevated cytotoxicity of +84.7 % (12.5 µM) and +100 % (25 and 50 µM) compared to 
the negative control. In comparison to 5-FUrd, the treatment with all concentrations of 
S.98 (12.5, 25 and 50 µM) significantly (p<0.001) raised the cytotoxicity on the human 
G28 glioma cells by +68.8 %, +75.5 % and +68.0 % (Fig. 20). 
The cytotoxicity on the human G28 glioma cells was significantly (p<0.001) increased 
by +24.8 %, +58.6 % and +74.1 % after the treatment with S.101 (12.5, 25 and 50 µM) 
compared to the negative control. In comparison to 5-FUrd, the incubation with S.101 
revealed a significant elevation of the cytotoxicity on the human G28 glioma cells by 
+33.7 % (25 µM, p<0.01) and +42.0 % (50 µM, p<0.001) (Fig. 20).  
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Figure 20: Cytotoxicity on human G28 glioma cells. 
Cytotoxicity (in % of the neg. control) of human G28 glioma cells after treatment (48 h) with 5-FUrd 
(positive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by SRB assay. Values are 
given (in % cytotoxicity of negative control [incubation with medium alone = 0 % cytotoxicity]) as mean ± 
SEM; **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; 
##
p<0.01, 
###
p<0.001, significance vs. 
5-FUrd at equal concentration; n=5 independent experiments assayed in quadruplicates. 
 
After the treatment with 5-FUrd (12.5, 25 and 50 µM) the human G112 glioma cells 
revealed a significant (p<0.001) increase of cytotoxicity by +35.4 %, +48.6 and +55.0% 
compared to the negative control (Fig. 21). 
Incubation with derivative S.18 significantly (p<0.001) enhanced the cytotoxicity on the 
human G112 glioma cells by +31.6 % (25 µM) and +99.5 % (50 µM) compared to the 
negative control. In comparison to 5-FUrd, the treatment with 50 µM S.18 significantly 
increased the cytotoxicity on the human G112 glioma cells by +44.5 % (p<0.001) (Fig. 
21). 
After the treatment with S.19 the human G112 glioma cells showed a significant 
(p<0.001) elevated cytotoxicity by +98.0 % (12.5 µM), +100 % (25 µM) and +99.7 % (50 
µM) compared to the negative control. In comparison to 5-FUrd, incubation with all 
three concentrations of S.19 led to a significant (p<0.001) enhancement of the cytotox-
icity on the human G112 glioma cells by +62.6 %, +51.8 % and +44.6 % (Fig. 21).  
After the incubation of the human G112 glioma cells with S.38 25 and 50 µM the cyto-
toxicity was significantly (p<0.001) raised by +68.9 % and +99.7 % compared to the 
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negative control. In comparison to 5-FUrd, only the treatment with 50 µM S.38 signifi-
cantly (p<0.001) increased the cytotoxicity on the human G112 glioma cells by +44.7 % 
(Fig. 21). 
The treatment with derivative S.98 12.5, 25 and 50 µM led to a significant (p<0.001) 
boost of the cytotoxicity on the human G112 glioma cells by +89.8 %, +100 % and 
+96.9 % compared to the negative control. In comparison to 5-FUrd, the incubation 
with all three concentrations of S.98 significantly (p<0.001) raised the cytotoxicity on 
the human G112 glioma cells by +54.4 %, +51.5 % and +41.9 % (Fig. 21). 
After the treatment with S.101 the human G112 glioma cells showed a significant 
(p<0.001) rise of the cytotoxicity by +36.6 % (12.5 µM), +61.6 % (25 µM) and +87.3 % 
(50µM) compared to the negative control. In comparison to 5-FUrd, only the incuba-
tion with 50 µM S.101 significantly (p<0.001) increased the cytotoxicity on the human 
G112 glioma cells by +32.3 % (Fig. 21). 
 
Figure 21: Cytotoxicity on human G112 glioma cells. 
Cytotoxicity (in % of the neg. control) on human G112 glioma cells after treatment (48 h) with 5-FUrd 
(positive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by SRB assay. Values are 
given (in % cytotoxicity of negative control [incubation with medium alone = 0 % cytotoxicity]) as mean ± 
SEM; ***p<0.001, significance vs. 0.25 % DMSO control; 
###
p<0.001, significance vs. 5-FUrd at equal 
concentration; n=5 independent experiments assayed in quadruplicates. 
Through the treatment with 5-FUrd the cytotoxicity on the human U251 glioma cells 
was significantly (p<0.001) enhanced by +90.7 % (12.5 µM), +97.4 % (25 µM) and +96.7 
% (50 µM) compared to the negative control (Fig. 22). 
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The human U251 glioma cells revealed a significant (p<0.001) boost of the cytotoxicity 
by +91.6 % and +93.9% after treatment with 25 or 50 µM of S.18, compared to the 
negative control (Fig. 22). 
After the incubation with derivative S.19 the cytotoxicity on the human U251 glioma 
cells was significantly (p<0.001) increased by +97.3 % (12.5 µM), +100 % (25 µM) and 
+99.4 % (50 µM) compared to the negative control (Fig. 22). 
The human U251 glioma cells showed a significant boost of the cytotoxicity by +79.0 % 
(12.5 µM, p<0.01), +100 % (25 µM, p<0.001) and +98.8 % (50 µM, p<0.001) after the 
treatment with S.38, compared to the negative control (Fig. 22). 
The treatment with S.98 showed a significant (p<0.001) enhanced cytotoxicity on the 
human U251 glioma cells by +91.4 % (12.5 µM) and +100 % (25 and 50 µM) compared 
to the negative control (Fig. 22). 
Incubation of the human U251 glioma cells  with S.101 12.5, 25 and 50 µM led to a 
significant rise of the cytotoxicity by +69.5 % (p<0.01), +95.9% (p<0.001) and +95.9 % 
(p<0.001) compared to the negative control (Fig. 22). 
 
Figure 22: Cytotoxicity on human U251 glioma cells. 
Cytotoxicity (in % of the neg. control) on human U251 glioma cells after treatment (48 h) with 5-FUrd 
(positive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by SRB assay. Values are 
given (in % cytotoxicity of negative control [incubation with medium alone = 0 % cytotoxicity]) as mean ± 
SEM; **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; n=5 independent experiments as-
sayed in quadruplicates. 
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The incubation of the human U87 glioma cells with 5-FUrd 12.5, 25 and 50 µM resulted 
in a significant (p<0.001) boost of the cytotoxicity by +85.9 %, +92.0 % and +92.4 % 
compared to the negative control (Fig. 23). 
After the treatment with S.18 the human U87 glioma cells showed a significant eleva-
tion of the cytotoxicity by +8.8 % (12.5 µM, p<0.05), +66.8 % (25 µM, p<0.01) and +100 
% (50 µM, p<0.001) compared to the negative control. In comparison to 5-FUrd, only 
the incubation with 50 µM S.18 led to a significant (p<0.01) increase of the cytotoxicity 
on the human U87 glioma cells by +8.4 % (Fig. 23). 
The human U87 glioma cells showed a significant (p<0.001) increase of the cytotoxicity 
by +92.8 % (12.5 µM) and +100 % (25 and 50 µM) after the incubation with S.19, com-
pared to the negative control. In comparison to 5-FUrd, the treatment with S.19 25 
and 50 µM significantly (p<0.01) raised the cytotoxicity on the human U87 glioma cells 
by +9.1% and +8.7 % (Fig. 23). 
After the incubation with derivative S.38 (12.5, 25 and 50 µM) the cytotoxicity was 
significantly increased by +26.9 % (p<0.01), +69.5 % (p<0.01) and +100 % (p<0.001) 
compared to the negative control. In comparison to 5-FUrd, only the treatment with 
50 µM S.38 significantly enhanced the cytotoxicity on the human U87 glioma cells by 
+8.7 % (p<0.01) (Fig. 23). 
The treatment of the human U87 glioma cells with S.98 revealed a significant 
(p<0.001) elevation of the cytotoxicity by +88.4 % (12.5 µM) and +100 % (25 and 50 
µM) compared to the negative control. In comparison to 5-FUrd, incubation with S.98 
25 and 50 µM significantly (p<0.01) increased the cytotoxicity on the human U87 glio-
ma cells by +9.2% and +8.4 % (Fig. 23).  
After the treatment with S.101 the human U87 glioma cells revealed a significant 
(p<0.001) enhancement of the cytotoxicity by +64.8 (12.5 µM), +80.2 % (25 µM) and 
+95.8 % (50 µM) compared to the negative control (Fig. 23). 
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Figure 23: Cytotoxicity on human U87 glioma cells. 
Cytotoxicity (in % of the neg. control) on human U87 glioma cells after treatment (48 h) with 5-FUrd 
(positive control) or the derivatives S.18, S.19, S.38, S.98 and S.101 measured by SRB assay. Values are 
given (in % cytotoxicity of negative control [incubation with medium alone = 0 % cytotoxicity]) as mean ± 
SEM; as mean ± SEM; *p<0.05, **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO control; 
##
p<0.01 
significance vs. 5-FUrd at equal concentration; n=5 independent experiments assayed in quadruplicates. 
 
4.4. Effects of the novel derivatives on the induction of apoptosis or 
necrosis  
4.4.1. Effects of the novel derivatives on the rate of apoptotic and 
necrotic cells  
For the analysis of the induction of apoptosis or necrosis a triple staining with YO-
PRO®-1, propidium iodine (PI) and Hoechst 33342 (H) was performed. The induction of 
apoptosis and necrosis in rat BT4Ca glioma cells was measured after an incubation of 
48 h with the derivatives under test at a concentration range of 12.5-50 µM; the pro-
apoptotic camptothecin (1 µM) was used as a positive control. 
All derivatives were solubilized in DMSO; hence a DMSO control was performed using 
medium with 0.25 % DMSO, corresponding to the concentration of DMSO in 50 µM 
maximal working concentration of the derivatives under test.  
Incubation of rat BT4Ca glioma cells with 0.25 % DMSO did not significantly affect the 
cell amount compared to the negative control (incubation with medium alone) (Fig. 
24). The incubation of the rat BT4Ca glioma cells with 1 µM camptothecin resulted in a 
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significant decrease of the cell amount by -48.5 % (p<0.001) compared to the negative 
control (Fig. 24). The treatment with 5-FUrd 12.5, 25 and 50 µM revealed a significant 
(p<0.001) loss of the rat BT4Ca glioma cells by -67.4 %, -69.6 % and -71.1 % compared 
to the negative control. In comparison to camptothecin (apoptosis positive control), 
the incubation with 5-FUrd significantly reduced the amount of the rat BT4Ca glioma 
cells by -18.9 % (12.5µM, p<0.01), -21.1 % (25µM, p<0.001) and -22.6 % (50µM, 
p<0.001) (Fig. 24). 
Figure 24: Cell amount of rat BT4Ca 
glioma cells after treatment with 5-
FUrd. 
Cell amount of rat BT4Ca glioma 
cells after 48 h incubation with 5-
FUrd, DMSO 0.25 % and camptoth-
ecin, determined by measuring the 
Hoechst fluorescence at 
Ex.355/Em.465 nm. Values are given 
(in % cells of neg. control [incuba-
tion with medium alone; = 100 %]) 
as mean +SEM; ***p<0.001 signifi-
cance vs. 0.25 % DMSO control; 
°°p<0.01, °°°p<0.001 significance vs. 
1µM camptothecin (apoptosis posi-
tive control); n=5 independent ex-
periments assayed in quadrupli-
cates 
Incubation of rat BT4Ca glioma cells with 0.25 % DMSO did not significantly affect the 
apoptotic cell rate compared to the negative control (Fig. 25). The incubation of rat 
BT4Ca glioma cells with the camptothecin (1 µM) induced a significant (p<0.01) +2.15-
fold increase of the apoptotic cell rate compared to the negative control (Fig. 25). The 
incubation of the rat BT4Ca glioma cells with 5-FUrd 12.5, 25 and 50 µM revealed a 
significant boost of the apoptotic cell rate by +3.08- (p<0.001), +3.31- (p<0.001) and 
+3.42-fold (p<0.01) compared to the negative control. In comparison to camptothecin, 
the treatment with 25 and 50 µM 5-FUrd significantly (p<0.05) raised the rate of apop-
totic rat BT4Ca glioma cells by +1.54- and +1.60-fold (Fig. 25). 
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Figure 25: Apoptotic cell rate of rat 
BT4Ca glioma cells after treatment 
with 5-FUrd. 
Rate of apoptotic cells measured by 
fluorometric quantification of YO-
PRO®-1 normalized with Hoechst in 
rat BT4Ca glioma cells after 48 h 
treatment with 5-FUrd, DMSO 0.25 
% and camptothecin. Values are 
given in fluorescence intensity ratio 
of YO-PRO®-1 (Ex.535/Em.617 nm) / 
Hoechst (Ex.355/Em.465 nm) as 
mean + SEM; **p<0.01, ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °p<0.05 significance vs. 1µM 
camptothecin (apoptosis positive 
control); n=5 independent experi-
ments assayed in quadruplicates. 
 
Incubation of rat BT4Ca glioma cells with 0.25 % DMSO did not significantly affect the 
necrotic cell rate compared to the negative control (incubation with medium alone) 
(Fig. 26). The incubation with camptothecin (1 µM) showed a significant (p<0.05) in-
crease of the necrotic rat BT4Ca glioma cell rate by +3.75-fold compared to the nega-
tive control (Fig. 26). The treatment of the rat BT4Ca glioma cells with 12.5, 25 or 50 
µM 5-FUrd led to a significant increase of the necrotic cell rate by +4.16- (p<0.001), 
+4.45- (p<0.01) and +5.52-fold (p<0.001) compared to the negative control. Moreover, 
incubation of rat BT4Ca glioma cells with 50 µM 5-FUrd significantly (p<0.01) raised 
the rate of necrotic cells +1.47-fold in comparison to camptothecin (Fig. 26). 
Figure 26: Necrotic cell rate of rat 
BT4Ca glioma cells after treatment 
with 5-FUrd. 
Rate of necrotic cells measured by 
fluorometric quantification of PI 
normalized with Hoechst in rat 
BT4Ca glioma cells after treatment 
with 5-FUrd, DMSO 0.25 % and 
camptothecin. Values are given in 
fluorescence intensity ratio of PI 
(Ex.350/Em.462 nm) / Hoechst 
(Ex.355/Em.465 nm) as mean + 
SEM; *p<0.05, **p<0.01, 
***p<0.001 significance vs. 0.25 % 
DMSO control; °°p<0.01 significance 
vs. 1µM camptothecin (apoptosis 
positive control); n=5 independent           
experiments assayed in quadruplicates.  
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The treatment of the rat BT4Ca glioma cells with S.18 25 or 50 µM significantly 
(p<0.001) decreased the cell amount by -50.7 %, and -72.8 % compared to the negative 
control. The incubation with 12.5 µM S.18 did not show any significant effects on the 
rat BT4Ca glioma cells. In comparison to camptothecin, only the treatment of rat 
BT4Ca glioma cells with 50µM S.18 significantly (p<0.05) reduced the cell amount by -
24.3 % (Fig. 27). 
Figure 27: Cell amount in rat BT4Ca 
glioma cells after treatment with 
S.18. 
Cell amount of rat BT4Ca glioma 
cells after 48 h incubation with S.18, 
DMSO 0.25 % and camptothecin, 
determined by measuring the 
Hoechst fluorescence at 
Ex.355/Em.465 nm. Values are given 
(in % cells of neg. control [incuba-
tion with medium alone; = 100 %]) 
as mean +SEM; ***p<0.001 signifi-
cance vs. 0.25 % DMSO control; 
°°p<0.01, °°°p<0.001 significance vs. 
1µM camptothecin (apoptosis posi-
tive control); n=5 independent ex-
periments assayed in quadruplicates 
 
Treatment of the rat BT4Ca glioma cells with S.18 25 and 50 µM showed a significant 
increase of the apoptotic cell rate by +2.03- (p<0.01) and +3.64-fold (p<0.001) com-
pared to the negative control. The incubation with 12.5 µM S.18 did not show any sig-
nificant effects on the rat BT4Ca glioma cells. In comparison to camptothecin the 
treatment of the rat BT4Ca glioma cells with S.18 raised only at the concentrations of 
50 µM the rate of apoptotic cells significantly (p<0.001) by +1.7-fold (Fig. 28). 
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Figure 28: Apoptotic cell rate of rat 
BT4Ca glioma cells after treatment 
with S.18. 
Rate of apoptotic cells measured by 
fluorometric quantification of YO-
PRO®-1 normalized with Hoechst in 
rat BT4Ca glioma cells after 48 h 
treatment with S.18, DMSO 0.25 % 
and camptothecin. Values are given in 
fluorescence intensity ratio of YO-
PRO®-1 (Ex.535/Em.617 nm) / 
Hoechst (Ex.355/Em.465 nm) as mean 
+ SEM; **p<0.01, ***p<0.001 signifi-
cance vs. 0.25 % DMSO control; 
°p<0.05 significance vs. 1µM camp-
tothecin (apoptosis positive control); 
n=5 independent experiments as-
sayed in quadruplicates. 
 
The incubation of the rat BT4Ca glioma cells with S.18 25 and 50 µM induced a signifi-
cant boost of the necrotic rate by +2.27- (p<0.01) and +6.15-fold (p<0.001) compared 
to the negative control. The treatment with 12.5 µM S.18 did not show any significant 
effects on the rat BT4Ca glioma cells. In comparison to camptothecin, the incubation of 
the rat BT4Ca glioma cells with S.18 showed at the concentrations of 50 µM a signifi-
cant (p<0.001) rise of the necrotic rate by +1.64-fold (Fig. 29). 
Figure 29: Necrotic cell rate of rat 
BT4Ca glioma cells after treatment 
with S.18. 
Rate of necrotic cells measured by 
fluorometric quantification of PI 
normalized with Hoechst in rat BT4Ca 
glioma cells after treatment with 5-
FUrd, DMSO 0.25 % and camptothe-
cin. Values are given in fluorescence 
intensity ratio of PI (Ex.350/Em.462 
nm) / Hoechst (Ex.355/Em.465 nm) as 
mean + SEM; *p<0.05, **p<0.01, 
***p<0.001 significance vs. 0.25 % 
DMSO control; °°p<0.01 significance 
vs. 1µM camptothecin (apoptosis 
positive control); n=5 independent 
experiments assayed in quadrupli-
cates. 
The incubation of the rat BT4Ca glioma cells with S.19 12.5, 25 and 50 µM revealed a 
significant (p<0.001) loss of the cell amount by -40.3 %, -72.4 % and -62.3 % compared 
to the negative control. In comparison to camptothecin, only the treatment of the rat 
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BT4Ca glioma cells with 25 µM S.19 significantly (p<0.001) decreased the cell amount 
by -23.9 % (Fig. 30). 
Figure 30: Cell amount in rat BT4Ca 
glioma cells after treatment with 
S.19. 
Cell amount of rat BT4Ca glioma 
cells after 48 h incubation with S.19, 
DMSO 0.25 % and camptothecin, 
determined by measuring the 
Hoechst fluorescence at 
Ex.355/Em.465 nm. Values are giv-
en (in % cells of neg. control [incu-
bation with medium alone; = 100 
%]) as mean +SEM; ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °°p<0.01, °°°p<0.001 signifi-
cance vs. 1µM camptothecin (apop-
tosis positive control); n=5 inde-
pendent experiments assayed in 
quadruplicates 
The treatment of the rat BT4Ca glioma cells with S.19 12.5, 25 and 50 µM raised the 
apoptotic rate significantly by +1.80- (p<0.05), +3.85- (p<0.001) and +2.68-fold 
(p<0.001) compared to the negative control. In comparison to camptothecin, incuba-
tion with S.19 (25 and 50 µM) significantly (p<0.05) enhanced the rate of the apoptotic 
rat BT4Ca glioma cells by +1.79- and +1.25-fold (Fig. 31). 
Figure 31: Apoptotic cell rate of rat 
BT4Ca glioma cells after treatment 
with S.19. 
Rate of apoptotic cells measured by 
fluorometric quantification of YO-
PRO®-1 normalized with Hoechst in 
rat BT4Ca glioma cells after 48 h 
treatment with S.19, DMSO 0.25 % 
and camptothecin. Values are given 
in fluorescence intensity ratio of 
YO-PRO®-1 (Ex.535/Em.617 nm) / 
Hoechst (Ex.355/Em.465 nm) as 
mean + SEM; **p<0.01, ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °p<0.05 significance vs. 1µM 
camptothecin (apoptosis positive 
control); n=5 independent experi-
ments assayed in quadruplicates. 
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The incubation of the rat BT4Ca glioma cells with S.19 25 and 50 µM induced a signifi-
cant boost of the necrotic rate by +9.45- (p<0.001) and +5.89-fold (p<0.01) compared 
to the negative control. The treatment with 12.5 µM S.19 did not show any significant 
effects on the rat BT4Ca glioma cells. In comparison to camptothecin, incubation of the 
rat BT4Ca glioma cells with S.19 (25 and 50 µM) revealed a significant increase of the 
necrotic rate by +2.52- (p<0.001) and +1.57-fold (p<0.05). Additionally, compared to 5-
FUrd the incubation with S.19 25 µM led to a significant (p<0.001) enhancement of the 
necrotic rate of the rat BT4Ca glioma cells by +2.12-fold (Fig. 32). 
Figure 32: Necrotic cell rate of rat 
BT4Ca glioma cells after treatment 
with S.19. 
Rate of necrotic cells measured by 
fluorometric quantification of PI nor-
malized with Hoechst in rat BT4Ca 
glioma cells after treatment with 5-
FUrd, DMSO 0.25 % and camptothe-
cin. Values are given in fluorescence 
intensity ratio of PI (Ex.350/Em.462 
nm) / Hoechst (Ex.355/Em.465 nm) as 
mean + SEM; *p<0.05, **p<0.01, 
***p<0.001 significance vs. 0.25 % 
DMSO control; °°p<0.01 significance 
vs. 1µM camptothecin (apoptosis 
positive control); n=5 independent 
experiments assayed in quadrupli-
cates. 
 
The incubation of the rat BT4Ca glioma cells with S.38 25 and 50 µM showed a signifi-
cant decrease of the cell amount by -53.9 % (p<0.01) and -74.8 % (p<0.001) compared 
to the negative control. The treatment with 12.5 µM S.38 did not show any significant 
effects on the rat BT4Ca glioma cells. In comparison to camptothecin, only the incuba-
tion with 50 µM S.38 significantly (p<0.001) lowered the cell amount of the rat BT4Ca 
glioma cells by -26.3 % (Fig. 33). 
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Figure 33: Cell amount in rat BT4Ca 
glioma cells after treatment with 
S.38. 
Cell amount of rat BT4Ca glioma 
cells after 48 h incubation with 
S.38, DMSO 0.25 % and camptothe-
cin, determined by measuring the 
Hoechst fluorescence at 
Ex.355/Em.465 nm. Values are 
given (in % cells of neg. control 
[incubation with medium alone; = 
100 %]) as mean +SEM; ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °°p<0.01, °°°p<0.001 signifi-
cance vs. 1µM camptothecin (apop-
tosis positive control); n=5 inde-
pendent experiments assayed in 
quadruplicates 
 
The treatment of the rat BT4Ca glioma cells with S.38 25 and 50 µM significantly raised 
the apoptotic rate by +2.47- (p<0.05) and +4.01-fold (p<0.01) compared to the nega-
tive control. Incubation with 12.5 µM S.38 did not show any significant effects on the 
rat BT4Ca glioma cells. In comparison to camptothecin, the treatment with S.38 signifi-
cantly (p<0.01) increased only at the concentrations of 50 µM the rate of apoptotic rat 
BT4Ca glioma cells by +1.87-fold (Fig. 34). 
Figure 34: Apoptotic cell rate of rat 
BT4Ca glioma cells after treatment 
with S.38. 
Rate of apoptotic cells measured by 
fluorometric quantification of YO-
PRO®-1 normalized with Hoechst in 
rat BT4Ca glioma cells after 48 h 
treatment with S.38, DMSO 0.25 % 
and camptothecin. Values are given 
in fluorescence intensity ratio of 
YO-PRO®-1 (Ex.535/Em.617 nm) / 
Hoechst (Ex.355/Em.465 nm) as 
mean + SEM; **p<0.01, ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °p<0.05 significance vs. 1µM 
camptothecin (apoptosis positive 
control); n=5 independent experi-
ments assayed in quadruplicates. 
 
 
  4. Results 
74 
 
0,00
0,10
0,20
0,30
0,40
neg.
control
DMSO Campto.
1µM
S.38
12.5µM
S.38
25µM
S.38
50µM
N
e
cr
o
ti
c 
ce
ll 
ra
te
 
(F
lu
o
re
sc
e
n
ce
 P
I/
H
o
e
ch
st
) 
 
** 
* 
°°° ### 
The incubation of the rat BT4Ca glioma cells with S.38 50 µM induced a significant 
boost of the necrotic rate by +9.54-fold (p<0.01) compared to the negative control. 
The treatment with 12.5 and 25 µM S.38 did not show any significant effects on the rat 
BT4Ca glioma cells. In comparison to camptothecin, incubation with S.38 50µM re-
vealed a significant enhancement of the necrotic rate of the rat BT4Ca glioma cells by 
+2.55-fold (p<0.001). Additionally, compared to 5-FUrd (Fig. 26), the treatment with 
S.38 50 µM led to a significant (p<0.001) increase of the necrotic rate of the rat BT4Ca 
glioma cells by +1.73-fold (Fig. 35). 
 
Figure 35: Necrotic cell rate of rat 
BT4Ca glioma cells after treatment 
with S.38. 
Rate of necrotic cells measured by 
fluorometric quantification of PI 
normalized with Hoechst in rat BT4Ca 
glioma cells after treatment with 5-
FUrd, DMSO 0.25 % and camptothe-
cin. Values are given in fluorescence 
intensity ratio of PI (Ex.350/Em.462 
nm) / Hoechst (Ex.355/Em.465 nm) as 
mean + SEM; *p<0.05, **p<0.01, 
***p<0.001 significance vs. 0.25 % 
DMSO control; °°p<0.01 significance 
vs. 1µM camptothecin (apoptosis 
positive control); n=5 independent 
experiments assayed in quadrupli-
cates. 
 
 
The incubation of the rat BT4Ca glioma cells with S.98 12.5, 25 and 50 µM revealed a 
significant (p<0.001) loss of the cell amount by -63.6 %, -77.1 % and -76.2 % compared 
to the negative control. In comparison to camptothecin, the treatment with S.98 (12.5, 
25 and 50 µM) significantly decreased the cell amount of the rat BT4Ca glioma cells by 
-15.1 % (p<0.05), -28.6 % (p<0.001) and -27.7 % (p<0.001) (Fig. 36). Moreover, com-
pared to 5-FUrd, (Fig. 24) incubation with S.98 25 µM led to a significant (p<0.001) de-
crease of cell amount of the rat BT4Ca glioma cells by -7.5 % (Fig. 36). 
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Figure 36: Cell amount in rat BT4Ca 
glioma cells after treatment with 
S.98. 
Cell amount of rat BT4Ca glioma 
cells after 48 h incubation with S.98, 
DMSO 0.25 % and camptothecin, 
determined by measuring the 
Hoechst fluorescence at 
Ex.355/Em.465 nm. Values are giv-
en (in % cells of neg. control [incu-
bation with medium alone; = 100 
%]) as mean +SEM; ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °°p<0.01, °°°p<0.001 signifi-
cance vs. 1µM camptothecin (apop-
tosis positive control); n=5 inde-
pendent experiments assayed in 
quadruplicates 
 
The treatment of the rat BT4Ca glioma cells with S.98 12.5, 25 and 50 µM led to a sig-
nificant rise of the apoptotic rate by +3.19- (p<0.01), +4.67- (p<0.001) and +4.47-fold 
(p<0.001) compared to the negative control. In comparison to camptothecin, the incu-
bation with 25 and 50 µM S.98 significantly (p<0.05) increased the rate of apoptotic rat 
BT4Ca glioma cells by +2.17- and +2.08-fold (Fig. 37).  
Figure 37: Apoptotic cell rate of rat 
BT4Ca glioma cells after treatment 
with S.98. 
Rate of apoptotic cells measured by 
fluorometric quantification of YO-
PRO®-1 normalized with Hoechst in 
rat BT4Ca glioma cells after 48 h 
treatment with S.98, DMSO 0.25 % 
and camptothecin. Values are given 
in fluorescence intensity ratio of YO-
PRO®-1 (Ex.535/Em.617 nm) / 
Hoechst (Ex.355/Em.465 nm) as 
mean + SEM; **p<0.01, ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °p<0.05 significance vs. 1µM 
camptothecin (apoptosis positive 
control); n=5 independent experi-
ments assayed in quadruplicates. 
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The incubation of the rat BT4Ca glioma cells with S.98 12.5, 25 and 50 µM revealed a 
significant boost of the necrotic rate by +7.78- (p<0.001), +10.98- (p<0.001) and 
+11.78-fold (p<0.01) compared to the negative control. In comparison to camptothe-
cin, the treatment of the rat BT4Ca glioma cells with S.98 revealed at all three concen-
trations (12.5, 25 and 50 µM) a significant rise of the necrotic rate by +2.08- (p<0.05), 
+2.93- (p<0.001) and +3.14-fold (p<0.05). Additionally, compared to 5-FUrd (Fig. 26), 
the incubation with S.98 (12.5, 25 and 50 µM) led to a significant (p<0.001) increase of 
the necrotic rate of the rat BT4Ca glioma cells by +1.87- (p<0.05), +2.47- (p<0.001) and 
+2.13-fold (p<0.001) (Fig. 38). 
Figure 38: Necrotic cell rate of rat 
BT4Ca glioma cells after treatment 
with S.98. 
Rate of necrotic cells measured by 
fluorometric quantification of PI 
normalized with Hoechst in rat 
BT4Ca glioma cells after treatment 
with 5-FUrd, DMSO 0.25 % and 
camptothecin. Values are given in 
fluorescence intensity ratio of PI 
(Ex.350/Em.462 nm) / Hoechst 
(Ex.355/Em.465 nm) as mean + SEM; 
*p<0.05, **p<0.01, ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °°p<0.01 significance vs. 1µM 
camptothecin (apoptosis positive 
control); n=5 independent experi-
ments assayed in quadruplicates. 
 
The treatment of the rat BT4Ca glioma cells with S.101 12.5, 25 and 50 µM led to a 
significant decrease of the cell amount by -19.4 % (p<0.01), -41.2 % (p<0.001) and -
60.0 % (p<0.001) compared to the negative control. In comparison to camptothecin, 
only incubation with 50 µM S.101 showed a significant loss of the rat BT4Ca glioma 
cells by -11.5 % (p<0.05) (Fig. 39). 
 
 
 
 
 
  4. Results 
77 
 
0,0
0,5
1,0
1,5
2,0
2,5
3,0
3,5
4,0
neg.
control
DMSO Campto.
1µM
S.101
12.5µM
S.101
25µM
S.101
50µM
A
p
o
p
to
ti
c 
ce
ll 
ra
te
 
(F
lu
o
re
sc
e
n
ce
 Y
P/
H
o
ec
h
st
) 
 
*** 
*** 
** 
*** 
0
20
40
60
80
100
120
140
DMSO Campto.
1µM
S.101
12.5µM
S.101
25µM
S.101
50µM
C
e
ll 
am
o
u
n
t 
(i
n
 %
 o
f 
th
e 
n
eg
. c
o
n
tr
o
l)
 
*** 
*** 
*** 
** 
° 
Figure 39: Cell amount in rat BT4Ca 
glioma cells after treatment with 
S.101. 
Cell amount of rat BT4Ca glioma 
cells after 48 h incubation with 
S.101, DMSO 0.25 % and camptoth-
ecin, determined by measuring the 
Hoechst fluorescence at 
Ex.355/Em.465 nm. Values are giv-
en (in % cells of neg. control [incu-
bation with medium alone; = 100 
%]) as mean +SEM; ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °°p<0.01, °°°p<0.001 signifi-
cance vs. 1µM camptothecin (apop-
tosis positive control); n=5 inde-
pendent experiments assayed in 
quadruplicates 
 
The incubation of the rat BT4Ca glioma cells with S.101 12.5, 25 and 50 µM showed a 
significant (p<0.001) boost of the apoptotic rate by +1.25-, +1.74- and +2.49-fold com-
pared to the negative control. In comparison to camptothecin, the treatment with 
S.101 (12.5, 25 and 50 µM did not show any significant effects on the rat BT4Ca glioma 
cells (Fig. 40). 
Figure 40: Apoptotic cell rate of rat 
BT4Ca glioma cells after treatment 
with S.101. 
Rate of apoptotic cells measured by 
fluorometric quantification of YO-
PRO®-1 normalized with Hoechst in 
rat BT4Ca glioma cells after 48 h 
treatment with S.101, DMSO 0.25 % 
and camptothecin. Values are given 
in fluorescence intensity ratio of 
YO-PRO®-1 (Ex.535/Em.617 nm) / 
Hoechst (Ex.355/Em.465 nm) as 
mean + SEM; **p<0.01, ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °p<0.05 significance vs. 1µM 
camptothecin (apoptosis positive 
control); n=5 independent experi-
ments assayed in quadruplicates. 
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The treatment of the rat BT4Ca glioma cells with S.101 12.5, 25 and 50 µM revealed a 
significant increase of the necrotic rate by +1.20- (p<0.05), +1.62- (p<0.001) and +2.26-
fold (p<0.05) compared to the negative control. In comparison to camptothecin, incu-
bation with S.101 had no significant effects on the necrotic rate of the rat BT4Ca glio-
ma cells at all three concentrations (12.5, 25 and 50 µM) (Fig. 41). 
Figure 41: Necrotic cell rate rat 
BT4Ca glioma cells after treatment 
with S.101. 
Rate of necrotic cells measured by 
fluorometric quantification of PI 
normalized with Hoechst in rat 
BT4Ca glioma cells after treatment 
with 5-FUrd, DMSO 0.25 % and 
camptothecin. Values are given in 
fluorescence intensity ratio of PI 
(Ex.350/Em.462 nm) / Hoechst 
(Ex.355/Em.465 nm) as mean + SEM; 
*p<0.05, **p<0.01, ***p<0.001 
significance vs. 0.25 % DMSO con-
trol; °°p<0.01 significance vs. 1µM 
camptothecin (apoptosis positive 
control); n=5 independent experi-
ments assayed in quadruplicates. 
 
The pictures and evaluation of the second measuring technique (see description 
methods 3.3.1), showing that the measurements of the cytation are confirmed, can be 
found in the supplements S.150- 163 (Fig. 27-39).  
 
4.4.2. Effects of the novel derivatives on the active caspase 3 activity 
For the characterization of the induction of apoptosis, the activity of the key protein 
caspase 3 was determined. Hence the activity of caspase 3 in the rat BT4Ca glioma 
cells was estimated after an incubation of 48 h with the derivatives at a concentration 
range of 12.5-50 µM. The pro-apoptotic camptothecin (1 µM) was used as positive 
control. 
 At the end of the treatment (48 h) the rat BT4Ca glioma cells were additionally coun-
terstained with Hoechst 33342 without exchanging the medium, so no apoptotic cells 
were lost. The fluorescence was measured at 350 nm excitation/462 nm emission. The 
detected DEVD fluorescence was normalized against the Hoechst 33342 fluorescence 
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and the caspase activity was calculated in % of the negative control (= 0 % activity). All 
derivatives were solubilized in DMSO; hence a DMSO control was performed using 
medium with 0.25 % DMSO, corresponding to the concentration of DMSO in 50 µM 
maximal working concentration of the derivatives under test. 
After the incubation of the rat BT4Ca glioma cells with 0.25 % DMSO no significant 
effect on the activation of caspase 3 was observed, compared to the negative control 
(incubation with medium alone = 0 % activity of caspase 3) (Fig. 42-47). 
 
The treatment of the rat BT4Ca cells with 1 µM camptothecin significantly (p<0.05) 
increased the caspase 3 activity by +50.8 % compared to the negative control (Fig. 42). 
The treatment of rat BT4Ca glioma cells with 12.5, 25 or 50 µM 5-FUrd revealed a sig-
nificant (p<0.001) increase of the caspase 3 activity by +82.3 %, +90.8 % and +91.0 % 
compared to the negative control.  Incubation of rat BT4Ca glioma cells with 12.5, 25 
or 50 µM 5-FUrd showed also a significant (p<0.001) increase of the caspase 3 activity 
by +31.5 %, +39.9 % and +40.2 % compared to camptothecin (Fig. 42). 
 
Figure 42: Caspase 3 activity of rat 
BT4Ca glioma cells after treatment with 
5-FUrd. 
Caspase 3 activity measured by fluoro-
metric quantification of DEVD 
(Ex.502/Em.530 nm) normalized with 
Hoechst (Ex.355/Em.465 nm) in rat 
BT4Ca glioma cells after 48 h incubation 
with 5-FUrd, DMSO 0.25 % and camp-
tothecin. Values are given (in % activity 
of neg. control [incubation with medium 
alone; = 0 % activity]) as mean + SEM; 
*p<0.05, ***p<0.001, significance vs. 
0.25 % DMSO control, °°p<0.01, 
°°°p<0.001, significance vs. 1µM camp-
tothecin (apoptosis positive control); 
n=5 independent experiments assayed 
in quadruplicates. 
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After the incubation of the rat BT4Ca glioma cells with 50 µM S.18 the activity of 
caspase 3 was significantly increased by +57.3 % (p<0.05) compared to the negative 
control. The treatment with 12.5 and 25 µM S.18 did not reveal any significant effects 
on the caspase 3 activity in the rat BT4Ca glioma cells. Compared to camptothecin, 
incubation with S.18 did not show any significant effects (Fig. 43) on the caspase 3 ac-
tivity in the rat BT4Ca glioma cells.  
Figure 43: Caspase 3 activity of rat 
BT4Ca glioma cells after treatment 
with S.18. 
Caspase 3 activity measured by fluo-
rometric quantification of DEVD 
(Ex.502/Em.530 nm) normalized with 
Hoechst (Ex.355/Em.465 nm) in rat 
BT4Ca glioma cells after 48 h incuba-
tion with S.18, DMSO 0.25 % and 
camptothecin. Values are given (in % 
activity of neg. control [incubation 
with medium alone; = 0 % activity]) as 
mean + SEM; *p<0.05, ***p<0.001, 
significance vs. 0.25 % DMSO control; 
n=5 independent experiments assayed 
in quadruplicates. 
 
The treatment of the rat BT4Ca glioma cells with S.19 significantly (p<0.05) raised the 
caspase 3 activity by +54.8 % (25 µM) and +41.4 % (50 µM) compared to the negative 
control. Incubation with 12.5 µM S.19 did not show any significant effects on the rat 
BT4Ca glioma cells. Compared to camptothecin, the treatment with none of the con-
centration of S.19 led to a significant boost of the caspase 3 activity in the rat BT4Ca 
glioma cells (Fig. 44). 
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Figure 44: Caspase 3 activity of rat BT4Ca 
glioma cells after treatment with S.19. 
Caspase 3 activity in relation to cell Caspa-
se 3 activity measured by fluorometric 
quantification of DEVD (Ex.502/Em.530 
nm) normalized with Hoechst 
(Ex.355/Em.465 nm) in rat BT4Ca glioma 
cells after 48 h incubation with S.19, 
DMSO 0.25 % and camptothecin. Values 
are given (in % activity of neg. control 
[incubation with medium alone; = 0 % 
activity]) as mean + SEM; *p<0.05, 
***p<0.001, significance vs. 0.25 % DMSO 
control; n=5 independent experiments 
assayed in quadruplicates. 
 
 
The treatment of the rat BT4Ca glioma cells with 50 µM S.38 revealed a significant in-
crease (p<0.01) of the caspase 3 activity by + 56.2 % compared to the negative control. 
Incubation with 12.5 and 25 µM S.38 did not show any significant effects on the rat 
BT4Ca glioma cells. Compared to camptothecin, the treatment with none of the con-
centration of S.38 showed a significant increase of the caspase 3 activity in the rat 
BT4Ca glioma cells (Fig. 45). 
Figure 45: Caspase 3 activity of rat 
BT4Ca glioma cells after treatment 
with S.38. 
Caspase 3 activity measured by fluo-
rometric quantification of DEVD 
(Ex.502/Em.530 nm) normalized with 
Hoechst (Ex.355/Em.465 nm) in rat 
BT4Ca glioma cells after 48 h incuba-
tion with S.38, DMSO 0.25 % and 
camptothecin. Values are given (in % 
activity of neg. control [incubation with 
medium alone; = 0 % activity]) as mean 
+ SEM; *p<0.05, ***p<0.001, signifi-
cance vs. 0.25 % DMSO control; n=5 
independent experiments assayed in 
quadruplicates. 
 
The treatment of the rat BT4Ca glioma cells with S.98 (12.5, 25 and 50 µM) led to a 
significant increase of the caspase 3 activity by + 52.9 % (p<0.01), +75.9 % (p<0.001) 
and +61.7 % (p<0.01) compared to the negative control. In comparison to camptothe-
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cin, incubation with 25 µM S.98 significantly raised the caspase 3 activity by + 25.1 % 
(p<0.05) in the rat BT4Ca glioma cells (Fig. 46). 
Figure 46: Caspase 3 activity of rat 
BT4Ca glioma cells after treatment with 
S.98. 
Caspase 3 activity measured by fluoro-
metric quantification of DEVD 
(Ex.502/Em.530 nm) normalized with 
Hoechst (Ex.355/Em.465 nm) in rat 
BT4Ca glioma cells after 48 h incubation 
with S.98, DMSO 0.25 % and camptothe-
cin. Values are given (in % activity of neg. 
control [incubation with medium alone; 
= 0 % activity]) as mean + SEM; *p<0.05, 
***p<0.001, significance vs. 0.25 % 
DMSO control, °p<0.05, significance vs. 
1µM camptothecin (apoptosis positive 
control); n=5 independent experiments 
assayed in quadruplicates. 
 
The treatment of the rat BT4Ca glioma cells with 50 µM S.101 revealed a significant 
increase (p<0.01) of the caspase 3 activity by + 70.9 % compared to the negative con-
trol. Incubation with 12.5 and 25 µM S.101 did not show any significant effects on the 
rat BT4Ca glioma cells. Compared to camptothecin, the treatment with none of the 
concentration of S.101 revealed a significant increase of the caspase 3 activity in the 
rat BT4Ca glioma cells (Fig.47). 
Figure 47: Caspase 3 activity of rat 
BT4Ca glioma cells after treatment 
with S.101. 
Caspase 3 activity measured by fluo-
rometric quantification of DEVD 
(Ex.502/Em.530 nm) normalized with 
Hoechst (Ex.355/Em.465 nm) in rat 
BT4Ca glioma cells after 48 h incuba-
tion with 5-FUrd, DMSO 0.25 % and 
camptothecin. Values are given (in % 
activity of neg. control [incubation 
with medium alone; = 0 % activity]) as 
mean + SEM; *p<0.05, ***p<0.001, 
significance vs. 0.25 % DMSO control; 
n=5 independent experiments assayed 
in quadruplicates. 
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4.5. Effects of the novel derivatives on the proliferation 
4.5.1. Effects of the novel derivatives on the amount of proliferating 
cell nuclear antigen (PCNA) 
For the analysis of the effects of the derivatives on the proliferation the amount of 
PCNA in rat BT4Ca glioma cells was estimated after an incubation of 24 h with the de-
rivatives at a concentrations of 12.5 and 25 µM. For every experiment a DMSO control 
was done, to check the influence of the solvent DMSO. Compared to the negative con-
trol (incubation with medium alone = 100 %), no significant effects on the amount of 
PCNA for the used 0.063 % and 0.125 % DMSO control were observed. The PCNA 
amount was calculated in % of the negative control (= 100 %) and the significances are 
given compared to the according DMSO control as well as to 5-FUrd. 
 
After the treatment of the rat BT4Ca glioma cells with 5-FUrd an insignificant increase 
of the PCNA levels by +29.9 % (12.5 µM) and +24.7 % (25 µM) were observed com-
pared to the negative control (Fig. 51).  
Through the treatment of rat BT4Ca glioma cells with 12.5 µM S.18 an insignificant 
reduction of the PCNA content by -38.9 % was detected compared to the negative con-
trol. 
Whereas the incubation of rat BT4Ca glioma cells with 25 µM S.18 significantly 
(p<0.05) lowered the amount of PCNA by -66.6 % compared to the negative control. 
Additionally, compared to 5-FUrd, the treatment of the rat BT4Ca glioma cells with 25 
µM S.18 significantly (p<0.05) reduced the content of PCNA by -91.3 % (Fig. 51).  
After the incubation with 12.5 µM S.19 the level of PCNA in the rat BT4Ca glioma cells 
was insignificantly diminished by -43.0 % compared to the negative control.  
In contrast, the treatment with S.19 (25 µM) led to a significant (p<0.05) decrease of 
PCNA content in the rat BT4Ca glioma cells by -59.2 % compared to the negative con-
trol. Whereas, compared to 5-FUrd, the incubation of the rat BT4Ca glioma cells with 
both concentrations of S.19 (12.5 or 25 µM) significantly (p<0.05) diminished the level 
of PCNA by -72.2 % and -83.9 % (Fig. 51).  
Compared to the negative control, the treatment of the rat BT4Ca glioma cells with 
S.38 12.5 or 25 µM revealed an insignificant decrease of the PCNA amount by -56.0 % 
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and -70.3 %. But compared to 5-FUrd the incubation of the rat BT4Ca glioma cells with 
S.38 25 µM revealed a significant (p<0.05) reduction of PCNA level by -95.0 % (Fig. 51). 
Through the incubation of the rat BT4Ca glioma cells with 12.5 µM S.98 the PCNA con-
tent was insignificantly decreased by -30.0 % compared to the negative control. 
Whereas, after the treatment with S.98 (25 µM) the PCNA level in the rat BT4Ca glio-
ma cells was significantly (p<0.05) lowered by -96.4 % compared to the negative con-
trol. Moreover, compared to 5-FUrd, incubation of the rat BT4Ca glioma cells with 25 
µM S.98 showed also a significant (p<0.05) reduction of the PCNA level by -121.1 % 
(Fig. 51). 
The treatment of the rat BT4Ca glioma cells with 12.5 µM S.101 revealed an insignifi-
cant decrease of the PCNA level by -66.3 % compared to the negative control. Howev-
er, compared to 5-FUrd, incubation of the rat BT4Ca glioma cells with 12.5 µM S.101 
led to a significant (p<0.05) decrease of the PCNA level by -95.5 %. 
In contrast, the treatment with 25 µM S.101 insignificantly increased the PCNA content 
in the rat BT4Ca glioma by +29.1 % compared to the negative control (Fig. 51). 
 
Figure 48: PCNA content of rat BT4Ca glioma cells after treatment. 
PCNA content of rat BT4Ca glioma cells after 24 h incubation with DMSO, 5-FUrd, S.18, S.19, S.38, S.98 
or S.101 at the concentrations of 12.5 and 25 µM. Values are given (in % of neg. control [incubation with 
medium alone; = 100 %]) as mean + SEM; *p<0.05, significance vs. 0.625 % and 0.125 % DMSO, #p<0.05, 
significance vs. 5-FUrd at equal concentration; n=3 independent experiments assayed in duplicates. 
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4.6. Effects of the novel derivatives on the induction of oxidative stress  
4.6.1. Effects of the novel derivatives on the production of ROS 
We used this assay to determine the amount of generated ROS in rat BT4Ca glioma 
cells after treatment with the derivatives of interest at the concentrations of 12.5, 25 
and 50 µM.  
For every experiment a DMSO control was done, to check the effect of the solvent 
DMSO. Incubation of the rat BT4Ca glioma cells with 0.25% DMSO (DMSO control) for 
30 min, 1, 2, 3, 4, 5, 24 and 48 h showed no significant effects on the formation of ROS 
compared to the rat BT4Ca glioma cells incubated with medium alone (negative con-
trol) (Fig. 48).   
The treatment of the rat BT4Ca glioma cells with S.18 50 µM revealed a significant 
(p<0.05) boost of the ROS production after 24 and 48 h by +1.71- and +2.15-fold com-
pared to the negative control. Additionally, compared to 5-FUrd, the incubation of in 
the rat BT4Ca glioma cells with S.18 50 µM significantly (p<0.05) raised the ROS pro-
duction at the same time points (24 and 48 h) by +1.66- and 2.04-fold (Fig. 48). 
Incubation with derivative S.38 (50 µM) significantly (p<0.05) increased the ROS pro-
duction in the rat BT4Ca glioma cells after 24 and 48 h by +1.29- and 1.66-fold com-
pared to the negative control, but no significances against 5-FUrd were found (Fig. 48).  
The incubation of the rat BT4Ca glioma cells with 50 µM S.98 showed after 48 h a sig-
nificant (p<0.05) increase of the ROS production by +1.86-fold compared to the nega-
tive control. In comparison to 5-FUrd, the treatment with 50 µM S.98 significantly 
(p<0.05) increased the ROS production after 48 in the rat BT4Ca glioma cells by +1.77-
fold (Fig. 48). 
The incubation with other derivatives under test, 5-FUrd, S.19 and S.101, did not lead 
to any significant changes in the ROS production of the rat BT4Ca glioma cells com-
pared to the negative control or 5-FUrd (Fig. 48).  
  4. Results 
86 
 
 
Figure 49: ROS amount of rat BT4Ca glioma cells after treatment. 
ROS amount of rat BT4Ca glioma cells during the incubation (48 h) with 5-FUrd, S.18, S.19, S.38, S.98, 
and S.101 50 µM. Values are given as fluorescence-intensity of DCFDA (Ext.495nm/Em.529nm) as mean 
± SEM; *p<0.05 significance vs. 0.25 % DMSO control; 
#
p<0.05 significance vs. 5-FUrd at equal concen-
tration; n=5 independent experiments assayed in quadruplicates. 
After the treatment of the rat BT4Ca glioma cells with each derivative at lower concen-
trations (12.5 and 25 µM), no further significant effects on the production of ROS were 
measured, compared to the negative control. The results for the concentrations 12.5 
and 25 µM for each of the five derivatives can be found in the supplements page 164-
167 (Fig. 40-45). 
In addition to the kinetics of the production of ROS, we also examined the ROS amount 
compared to the cell amount at the end of the treatment (48 h) (Fig. 49). Although, 
after the treatment with the derivatives the amount of ROS is increased in the rat 
BT4Ca glioma cells, the cell amount is simultaneously decreased, compared to the 
negative control (Fig. 49).  
The treatment of the rat BT4Ca glioma cells with derivative 50 µM S.18 significantly 
raised the total ROS amount after 48 h by 2.15-fold (p<0.05) and led simultaneously to 
a significant (p<0.001) decrease of the cell amount by -3.62-fold compared to the neg-
ative control.  
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The incubation of rat BT4Ca glioma cells with 50 µM S.38 significantly (p<0.05) en-
hanced the total ROS amount by +1.66-fold and significantly (p<0.001) lowered the cell 
amount by -3.35-fold compared to the negative control. 
The treatment of the rat BT4Ca glioma cells with derivative 50 µM S.98 revealed a sig-
nificant (p<0.05) boost of the total ROS amount by +1.86-fold after 48 h and showed a 
significant (p<0.001) reduction of the cell amount by -3.73-fold compared to the nega-
tive control. 
The incubation of the rat BT4Ca glioma cells with the other derivatives, S.19, S.101 and 
5-FUrd (50 µM) did not significantly change the total amount of ROS compared to the 
negative control. However, the treatment of the rat BT4Ca glioma cells with 50 µM 
S.19, S.101 and 5-FUrd significantly decreased the cell amount by -2.48- (p<0.001), -
2.27- (p<0.01) and -3.21-fold (p<0.001) compared to the negative control. Hence, all 
derivatives raised the ROS production per cell (Fig. 49) and thus induced oxidative 
stress. 
Moreover, compared to 5-FUrd, the incubation of the rat BT4Ca glioma cells with 50 
µM S.18 or S.98 significantly (p<0.05) increased the ROS amount by +2.04 and +1.77 
(Fig.49).   
 
Figure 50: ROS and cell amount of rat BT4Ca glioma cells after 48 h treatment. 
ROS and cell amount of rat BT4Ca glioma cells after the incubation (48 h) with 5-FUrd, S.18, S.19, S.38, 
S.98, S.101 50 µM and 0.25 % DMSO. Values are given as fluorescence-intensity as mean ± SEM; 
*p<0.05, **p<0.01, ***p<0.001, significance vs. 0.25 % DMSO; 
#
p<0.05 significance vs. 5-FUrd at equal 
concentration; n=5 independent experiments assayed in quadruplicates. 
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4.6.2. Effects of the novel derivatives on the ratio of rGSH/GSSG 
Based on the results of the ROS assay, the rGSH/GSSG assay was performed, to deter-
mine if the GSH system is buffering the emerging ROS. The proportion of GSH and 
GSSG was determined by using spectrophotometry (Rahman, Kode & Biswas, 2006).  
Hence the  amount of the reduced and oxidized form of GSH in rat BT4Ca glioma cells 
was estimated after an incubation of 48 h with the derivatives at a concentrations of 
6.25 and 12.5 µM. For every experiment a DMSO control accordingly to derivative so-
lution was done, to check for the effect of the solvent DMSO on the intracellular redox 
state. Compared to the negative control (incubation with medium alone), no signifi-
cant effects on the ratio of rGSH/GSSG for the used 0.032 % and 0.063 % DMSO con-
trols were observed. The ratio of rGSH/GSSG was calculated in % of the negative con-
trol (= 100%) and the significances are given compared to the according DMSO control 
as well as to 5-FUrd. 
 
The treatment of the rat BT4Ca glioma cells with 12.5 µM 5-FUrd revealed a significant 
(p<0.05) reduction of the rGSH/GSSG ratio by -55.9 % compared to the negative con-
trol. The incubation of the rat BT4Ca glioma cells with 5-FUrd at the concentrations of 
6.25 µM did not show a significant effect on the ratio of rGSH/GSSG compared to the 
negative control (Fig. 50).  
After treatment of the rat BT4Ca glioma cells with 12.5 µM S.98 the ratio of 
rGSH/GSSH was significantly (p<0.001) decreased by -95.6 % compared to the negative 
control. Additionally, compared to 5-FUrd, incubation of the rat BT4Ca glioma cells 
with 12.5 µM S.98 significantly (p<0.001) lowered the ratio of rGSH/GSSG by -39.7 % 
(Fig. 50).  
Moreover, the incubation of the rat BT4Ca glioma cells with 12.5 µM S.101 also led to 
a significant (p<0.05) decrease of the rGSH/GSSG ratio by -45.3 % compared to the 
negative control (Fig. 50). 
Through treatment with the other derivatives under test, S.18, S.19 and S.38, no signif-
icant changes in the ratio of rGSH/GSSG in the rat BT4Ca glioma cells were observed, 
compared to the negative control or 5-FUrd (Fig. 50). 
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Figure 51: rGSH/GSSG ratio in rat BT4Ca glioma cells after treatment. 
Ratio of the reduced GSH (rGSH) and GSSG in rat BT4Ca glioma cells after 24 h incubation with DMSO, 5-
FUrd, S.18, S.19, S.38, S.98 and S.101 at the concentrations of 6.25 and 12.5 µM. Values are given (in % 
of neg. control [incubation with medium alone; = 100 %]) as mean + SEM; *p<0.05, ***p<0.001, signifi-
cance vs.  0.032 % and 0.063 % DMSO control, 
###
p<0.001, significance vs. 5-FUrd at equal concentration; 
n=3 independent experiments assayed in duplicates. 
4.7. Effects of the novel derivatives on the activation of NFκB  
4.7.1. Effects of the novel derivatives on the localization of NFκB 
p65  
This assay is primarily used to determine whether the NFκB signal pathway has been 
activated. Therefore the intracellular localization, nuclear or cytoplasmic, of the NFκB-
p65 subunit is analyzed by immunofluorescence.  The localization of NFκB-p65 in rat 
BT4Ca glioma cells was estimated after an incubation of 24 h with the derivatives at 
concentrations of 12.5 and 25 µM. For every experiment a DMSO control was done to 
check the influence of the solvent DMSO. Compared to the negative control (incuba-
tion with medium alone), no significant effects of 0.0625 % or 0.125 % DMSO on the 
localization of NFκB-p65 was detected. 
Moreover, after treatment (24 h) of the rat BT4Ca glioma cells with any of the five de-
rivatives or 5-FUrd no nuclear translocation of the subunit p65 was observed (see sup-
plements page 168-173, Fig. 46-51).  
Following, the localization of p65 after incubation with 25 µM S.98 compared to the 
incubation with medium (negative control) is shown as an example (Fig 52). 
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4.8. Effects of the novel derivatives on the migration  
4.8.1. Effects of the novel derivatives on the wound healing capac 
 
4.8. Effects of the novel derivatives on the migration 
4.8.1. Effects of the novel derivatives on the wound healing capacity 
This assay is used to determine the migratory capacity of the cells. Therefore “wound-
ing” was performed by scratching of a cell monolayer at the bottom of the well. The 
“wound” was photographed at time 0 and after 6 h of the treatment at the same loca-
tion. Hence, the migration was plotted as a percentage of wound closure (Fig. 53). 
The migration of rat BT4Ca glioma cells was estimated during an incubation of 6 h with 
the derivatives at concentrations of 12.5 and 25 µM. For every experiment a solution 
control was done, to check for the influence of the solvent DMSO. Compared to the 
negative control (incubation with medium alone), no significant effects on the migra-
tion were observed for the used DMSO concentrations 0.063 % and 0.13 % (equal con-
centration of DMSO to 12.5 and 25 µM substance solution). Below the wound at time 
point 0 and after 6 h of treatment with medium (neg. control) or 25µM S.98 are illus-
trated as representative images. 
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Figure 53: Wound healing of BT4Ca glioma cells  
Representative images of the Scratch or wound healing assay of rat BT4Ca glioma cells after 0h and 6h 
cultured with medium alone (A and B) and after treatment with S.98 25 µM (C and D) (magnification 
100x). 
 
With this assay we investigated the influence of the derivatives of interest on the mi-
gratory capacity of the rat BT4Ca glioma cells after treatment.  No difference between 
the migration ability after 6 h with e.g. S.98 25 µM compared to the negative control 
was observed (Fig 53). The other derivatives (S.18, S.19, S.38 and S.101) did not signifi-
cantly lower the migration ability of the rat BT4Ca glioma cells as well (Fig 54). 
 
Figure 54: Wound healing of rat BT4Ca glioma cells after treatment. 
Wound healing of rat BT4Ca glioma cells after 6 h during the incubation with medium (= neg. control) or 
DMSO, 5-FUrd, S.18, S.19, S.38, S.98 and S.101 at the concentrations of 12.5 and 25 µM. Values are 
given (in % of wound size at 0 h = 100 %) as mean + SEM; n=3 independent experiments. 
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5. Discussion 
In 2018, 18.1 million cancer cases were registered worldwide. With an estimated num-
ber of 9.6 million deceased patients, cancer was the second leading cause of death 
around the world (GLOBOCAN 2018). Nowadays, the clinics use chemotherapy as a 
standard technique for the treatment of cancer (Longley et al., 2003). 5-Fluorouracil 
(5-FU), developed by Charles Heidelberger in the 1950’s (Heidelberger et al., 1957),  is 
a chemotherapeutic agent widely used against a variety of malignant tumors (Tanaka 
et al., 2000) especially colon and breast cancer (Longley et al., 2003b; Yoon, 2005). But, 
besides its anti-cancer-impact as an effective antimetabolite, it carries along a wide 
range of unpleasant side effects (Focaccetti et al., 2015). 5-FU belongs to the fraction 
of molecules with low molecular weight. This class of molecules includes lipids, mono-
saccharides, second messengers or other natural products and metabolites as well as 
drugs and other xenobiotics and differs from macromolecules such as proteins (Na-
ture, 2019). Because of their low molecular weight, these substances are able to pass 
through the cell membrane easily. Once they have entered a cell, they can damage 
molecules, like proteins, the DNA or RNA and trigger cytotoxicity of cancer cells. (NIH, 
National Cancer Institute, 2019). Nevertheless, anticancer drugs with a small molecular 
weight still have several limitations such as adverse side effects, increased metabolism 
and nonspecific cytotoxicity, severe multidrug resistance and low bioavailability (Ja-
hangirian et al., 2019). Beside this, the penetration of the cell membrane is not only 
related to the size of the molecules but also depends on their polarity, lipophilicity, 
hydrophilicity, polar surface area, hydrogen bonding and charge (Lipinski et al., 2001; 
Yang & Hinner, 2016). Under the application of the rules of five (Lipinski et al., 2001) 
and based on the structure of the well-known 5-FU derivative 5-Fluorouridine (5-FUrd), 
as well as the nucleosides adenosine, cladribin, formycin, guanosine and inosine and 
others, Prof. Dr. Rosemeyer et al. designed and synthesized a various number of novel 
nucleolipids (Malecki & Rosemeyer, 2010; Rosemeyer et al., 2012; Rosemeyer & Mal-
ecki, 2012; Köstler et al., 2013; Malecki E. 2013; Malecki et al., 2013; Malecki, Viere & 
Rosemeyer, 2013; Malecki et al., 2014; Werz et al. 2013; Farhat et al., 2014; Knies et 
al., 2015a; Knies et al., 2015b; Farhat, 2016; Knies et al., 2016; Hammerbacher et al., 
2018; Knies et al., 2018; Rosemeyer et al., 2019; Reuter et al., 2019). These novel nu-
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cleolipids have been modified at several positions and bear different side chains, which 
influence the lipophilic and hydrophilic properties of the molecules. Thus, these modi-
fications alter the polarity and hopefully lead to a higher access into the cells and an 
improved penetrability through the blood-brain-barrier.  
Over the last six years, we investigated the effects of more than 120 of these novel 
synthesized nucleolipids on the viability of rat BT4Ca glioma cells, human GOS3 glioma 
cells and human THP1 immune cells (PMA-differentiated macrophages) (Farhat et al., 
2014; Knies et al., 2015a; Knies et al., 2015b; Knies et al., 2016; Hammerbacher et al., 
2018; Knies et al., 2018; Rosemeyer et al., 2019; Reuter et al., 2019). The PMA-
differentiated human THP1 macrophages represent effector cells of the innate im-
mune system and give first hints of possible side effects. The BT4Ca cells enable an 
insight on the effects towards rat glioma cells, to eventually use in a rat animal model, 
whereas the human GOS3 cells show the impact on human glioma cells. Subsequently, 
we selected derivatives, which had to fulfill two selection criteria: 
1. Efficiency comparable or stronger than 5-FUrd in inhibiting the viability or in-
ducing cytotoxicity on the above mentioned rat BT4Ca and human GOS3 glioma 
cell lines  
2. Minimally destructive towards the THP1 immune cells, indicating presumably 
low side effects 
Five derivatives (S. 18, 19, 38, 98 and 101) were selected to be further examined. In 
this study we compare the effects of these derivatives with the effects of 5-FUrd. Alt-
hough 5-FUrd (accordingly 5-FU) is used as a therapeutic agent against brain tumors 
(Lakkadwala & Singh, 2018; Roullin et al., 2004; Larner et al., 1991), it is not the com-
mon therapy of choice for gliomas. Temozolomide (TMZ) is currently considered to be 
the standard chemotherapeutic agent for the treatment of brain tumors (Fernandes et 
al., 2017; Portnow et al., 2009; NIH, National Cancer Institute, 2016). Despite, we used 
5-FUrd as the substance to compare, because it has a high structural similarity with our 
derivatives and thus presumably has a comparable mechanism of action (Weiss et al., 
2014). 
Cell membranes are described as complex and highly dynamic systems, which mainly 
consist out of several types of phospholipids and proteins (Cooper, 2000). It is known 
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that the morphological tumoral transformation goes along with changes in the lipid 
composition of the plasma membrane. Thus, this transformation might be also related 
to the malignancy of the tumor (Azordegan et al., 2013). In this study, rat BT4Ca glioma 
cells are used as a model of grade IV astrocytoma with high metastatic aggressiveness. 
Moreover, the cell lines used as model for human gliomas are represented by GOS3 
glioma cells, a mixed grade II/III astro-oligodendroglioma as well as G28 glioma cells 
from a gliosarcoma still expressing the glial fibrillary acidic protein (GFAP), a marker of 
astrocytic differentiation and expressed in astroglial tumors as well (Westphal et al., 
1988; Westphal et al., 1994). G112 glioma cells, also with intact GFAP expression, are 
classified as glioblastoma grade IV (Westphal et al., 1994). The U251 glioma cells, with 
morphological irregular cell shapes and long protrusions (Diao et al., 2019; Torsvik et 
al., 2014) as well as the U87 glioma cells, which move very fast and tend to aggregate 
as clusters, are classified as grade IV astrocytoma (Clark et al., 2010; Diao et al., 2019). 
Accordingly, the composition of the membrane lipids and the penetrability properties 
of derivatives across the plasma membrane may be different for these cell lines. 
Hence, the access of the derivatives across the cell membrane is suggested to depend 
on the size, symmetry and position of the modified side chains (especially the farnesyl 
chain) as well as the lipophilic and hydrophilic properties of the test derivatives, as 
observed in this study. But obviously it also depends on the metabolic characteristics 
of the cancer cell type. 
Regarding the amount of different derivatives (over 120) which include also purines, it 
is noticeable that the five selected derivatives, which are demonstrated to be more 
effective, belong to the group of pyrimidines. Furthermore, comparing the chemical 
structure of the derivatives in detail, it seems that there is no huge difference between 
the effects of derivatives derived from adenosine, inosine or formycin. Also the differ-
ent side chains, added to the ribose, do not seem to lead to a big difference in the ef-
fectiveness of the derivatives. Only the positions of the attached farnesyl chain at posi-
tion 9 (S.98) seems to trigger a high effectiveness against the rat as well as the human 
glioma cells.  
We were able to show, that 5-FUrd exhibits a cytostatic effect on the viability of the rat 
BT4Ca and human GOS3 glioma cells after 48 h (Figs. 12 and 13), whereas it shows dif-
ferent patterns of cytotoxicity depending on the tested human glioma cell lines (G28, 
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G112, U251, U87) at higher concentrations (12.5-50 µM) (Figs.14-17). The five selected 
derivatives (S. 18, 19, 38, 98 and 101) reveal cytotoxic effects on the viability of all six 
tested glioma cell lines (Fig. 14-17). The effects of the derivatives might be similar by 
trend throughout the cell lines, but seem to differ in intensity depending on the prolif-
eration rate. It looks like the faster the cells proliferate, the stronger are the effects on 
the viability. Nevertheless, the incubation with every selected derivative shows, at 
least at one concentration, a potent inhibition of the viability after 48 h, which is com-
parable or even stronger than the inhibition by 5-FUrd. However, the treatment with 
derivative S.19 and S.98 reveal the highest inhibitory effects on the cell viability, 
whereat S.98 is highly effective even at lower concentrations (1.56-6.25 µM).  
These results are in agreement with the observed cytotoxicity (Figs. 18-23), which rises 
along with the higher concentrations of the derivatives. Thus, we were able to show, 
that 5-FUrd and the five selected derivatives not only diminish the metabolic activity of 
the cells but also trigger some kind of cell death.  
Additionally, after treatment (48 h) of the rat BT4Ca glioma cells with the five selected 
derivatives (S. 18, 19, 38, 98 and 101) the cell amount, measured by the Hoechst stain-
ing (Merck, Sigma-Aldrich, 2019), also indicates a significant loss of cells depending on 
the concentration (12.5-50 µM) of the derivatives (Figs. 27, 30, 33, 36 and 39), whereas 
the treatment with 5-FUrd shows a consistent loss of cells at each concentration tested 
(Fig. 24). Hence, we analyzed several molecular mechanisms by exemplarily using rat 
BT4Ca glioma cells, to identify potential signaling effects of 5-FUrd and the five select-
ed derivatives. 
During cancer genesis, altered cells acquire and develop different mechanisms to 
evade cell death, which is described as one of the six hallmarks of cancer (Hanahan & 
Weinberg, 2011). 
Thus, malignantly transformed cells are able to encounter apoptosis, the programmed 
cell death. Physiologically apoptosis is necessary to eliminate damaged or abnormal 
cells (Fernald & Kurokawa, 2013). Defects of this ubiquitous cellular process can not 
only lead to the formation of cancer but also contribute to tumor metastasis and drug 
resistance (Wong, 2001). Hence the capacity of inducing apoptosis can be one benefi-
cial attribute of chemotherapeutic agents. In this context, we analyzed the induction of 
apoptosis through the treatment of the rat BT4Ca glioma cells with 5-FUrd or the five 
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selected derivatives (S. 18, 19, 38, 98 and 101). For the differentiation between the 
induction of apoptosis and necrosis we used a triple staining with YO-PRO®-1, propidi-
um iodine and Hoechst 33342. YO-PRO®-1 is a non-permeant fluorescent for intact 
cells. Due to apoptosis, the membrane becomes permeant and YO-PRO®-1 can enter 
the cells. Thus, YO-PRO®-1 marks late apoptosis. Whereas propidium iodine (PI) re-
mains impermeable to apoptotic and living cells but permeable for injured cells. Thus, 
PI serves as necrosis marker. Counterstaining with Hoechst 33342 allows the visualiza-
tion of cell nuclei. Hence, by measuring the fluorescence intensity of these three dyes 
allows to differentiate between the apoptotic cell rate and the rate of necrotic cells.  
According to this we showed, that incubation (48 h) with the five derivatives increase 
the amount of apoptotic rat BT4Ca glioma cells throughout ascending concentrations 
(Fig. 28, 31, 34, 37 and 40). The treatment with 5-FUrd shows a constant high level of 
apoptotic rat BT4Ca glioma cells at concentrations 12.5-50 µM (Fig. 25). This observa-
tion is in agreement with earlier results, showing that 5-FU induces cell death via apop-
tosis in several cell lines like colorectal cancer or oral epithelial cells (Mhaidat et al., 
2014; Tong et al., 2000, Voboril et al., 2004).   
Staining with PI also reveales an increase of the percentage of necrotic rat BT4Ca glio-
ma cells (Fig. 26, 29, 32, 35, 38 and 41). This increase of necrotic rat BT4Ca glioma cells 
could be due to the so-called secondary necrosis: At some point during apoptosis, the 
cell membrane breaks down and becomes permeable to propidium iodine, too. There-
fore, after 48 h of incubation with 5-FUrd or the selected derivatives the measurement 
might include some YO-PRO®-1/ propidium iodine double stained dead cells (Invitro-
gen™, 2010) explaining the observed higher amount of necrotic rat BT4Ca glioma cells. 
Thus, we decided to use another method to measure apoptotic cells, i.e. the detection 
of the activation of specific caspases. Caspase 3 is known as a key enzyme in the pro-
cess of apoptosis. It plays an important role for the apoptotic chromatin condensation 
and DNA fragmentation as well as the dismantling of the cell and the formation of 
apoptotic bodies (Porter & Jänicke, 1999). Hence, the activity of caspase 3 is crucial 
evidence for the induction of apoptosis. In our study we could show, that incubation 
with 5-FUrd or the five selected derivatives (S.18, 19, 38, 98 and 101; 12.5-50 µM) in-
duce a high activity of caspase 3 in rat BT4Ca glioma cells (Fig. 42-47). These results 
confirm our previous observations of the induction of apoptosis and indicate an apop-
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tosis mediated cell death of the rat BT4Ca glioma cells triggered by the treatment (48 
h) with 5-FUrd or the selected derivatives.  
Another hallmark of cancer, pivotal for the transformation of healthy cells into tumors 
cells and acquired during the multistep development of human tumors, is the capabil-
ity to sustain proliferative signaling (Hanahan & Weinberg, 2011). Thus, the capacity of 
inhibiting or preventing cell proliferation would be beneficial for anticancer drugs. The 
proliferating cell nuclear antigen (PCNA) is known to interact with several proteins in-
volved in cell-cycle progression. It also plays a crucial role for DNA synthesis during 
replication and is important for chromatin remodelling, DNA repair as well as sister-
chromatid cohesion (Kelman, 1997; Kubben et al., 1994; Boehm, Gildenberg & 
Wahington, 2017). Therefore, PCNA is essential for cell proliferation and thus often 
used as a marker.  
Hence, we analyzed the level of PCNA in the rat BT4Ca glioma cells after treatment (24 
h) with 5-FUrd or the five selected derivatives S. 18, 19, 38, 98 and 101. Interestingly, 
after 24 h of treatment all five selected derivatives under test (12.5 and 25 µM), inhibit 
the proliferation of rat BT4Ca glioma cells, indicated by a reduced amount of PCNA 
(Fig. 48). In contrast, the treatment (24 h) of the rat BT4Ca glioma cells with 5-FUrd 
(12.5 and 25 µM) does not reveal a decline of PCNA quantity (Fig. 48). Thus, at our ex-
perimental conditions 5-FUrd does not affect the proliferation rate of the rat BT4Ca 
glioma cells measured by PCNA. These results might explain the previous examined 
cytostatic effect of 5-FUrd on the viability of these glioma cells, described above. In 
this regard our results for 5-FUrd are in opposition to the documented inhibitory effect 
of 5-FU on the proliferation, which however were performed by using neuroblasts of 
the retinal margin (Negishi, 1994). Noticeable, our selected derivatives not only lead to 
a reduction of the cell amount by inducing apoptosis, but furthermore diminish the cell 
mass, because of an additional inhibition of the cell proliferation. 
 
Due to the high metabolic activity of cancer cells the cellular appearance of reactive 
oxygen species (ROS) is naturally elevated. It is further described that ROS is crucial for 
every stage of cancer development, including initiation, promotion, and progression 
(Kumari et al., 2018). On the other side, oxidative stress, induced by an excess of ROS, 
is described to play an essential role in apoptosis signaling (Kannan & Jain, 2000).  
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Thus, we examined the occurrence of oxidative stress in rat BT4Ca glioma cells upon 
treatment (48 h) with 5-FUrd and the selected derivatives S. 18, 19, 38, 98 and 101 at a 
concentration of 50 µM. In rat BT4Ca glioma cells the treatment with the five selected 
derivatives caused a tremendous increase of ROS per cell (Fig. 50). Especially the 
treatment with derivatives S.18, 19 and 98 (50 µM) induces an elevated production of 
ROS and consequently an induction of oxidative stress in this glioma cell line. The incu-
bation with 5-FUrd also elevates the level of ROS in the rat BT4Ca glioma cells, howev-
er not in the same extent as the derivatives (Fig. 50). These data indicate that 5-FUrd 
and especially the derivatives trigger the production of ROS in the rat BT4Ca glioma 
cells. Hence, the appearance of oxidative stress in rat BT4Ca glioma cells is increased 
through the treatment with the derivatives or 5-FUrd (50 µM). These observations go 
hand in hand with the former results, describing a raised level of intracellular oxidative 
stress induced by treatment with 5-FU in the salivary glands (Bomfin et al., 2017) and 
in the blood of patients with colorectal cancer (Koçer & Nazıroğlu, 2013) and associat-
ed with cell death induction. 
Additionally, it has been shown, that antioxidants can inhibit 5-FU –induced apoptosis 
(Fu et al., 2014). To maintain the balance of the cellular redox status, cancer cells es-
tablish a huge antioxidant system, including glutathione. Under physiological condi-
tions 98 % of the cellular glutathione (GSH) is in a reduced status. Due to oxidative 
stress, ROS can occur in large quantities. Thus the GSH acts as a scavenger, removing 
the free radicals and is thereby oxidized. Hence the ratio of reduced glutathione (rGSH) 
to oxidized glutathione (GSSG) is an important index for oxidative stress within a cell. It 
is generally accepted that the rGSH/GSSG ratio is a useful indicator of oxidative stress 
in cells and tissues (Owen & Butterfield, 2010). In this context, we additionally ana-
lyzed the intracellular glutathione redox status by determination of the rGSH/GSSG 
ratio in rat BT4Ca glioma cells after treatment (24 h) with 5-FUrd or the selected deriv-
atives S. 18, 19, 38, 98 and 101 (6.25 and 12.5 µM). Under physiological conditions the 
rGSH/GSSG ratio exceeds 100:1 in resting cells. With increased levels of oxidative 
stress, intracellular GSSG will accumulate, by the oxidation of two rGSH molecules to 
one GSSG and the rGSH/GSSG ratio will decrease (Forman et al., 2009). Thus, a low 
rGSH/GSSG ratio indicates a high occurrence of ROS and displays oxidative stress (Zitka 
et al., 2012). Due to the high cytotoxicity of 5-FUrd and the derivatives at the concen-
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trations of 25 and 50 µM, we were forced to treat the rat BT4Ca glioma cells with low-
er concentrations enabling us to collect enough material, particularly cells and pro-
teins. Therefore, we performed the rGSH/GSSG assay with lower concentrations (6.25 
and 12.5µM) to determine the data of interest. Interestingly, the treatment with de-
rivative S. 18, 19 and 38 does not reveal any effect on the rGSH/GSSG ratio in the rat 
BT4Ca glioma cells (Fig. 51), although the treatment elevates the ROS level per cell. 
This unaffected ratio of rGSH/GSSG could be explained by the lower concentrations 
(6.25 and 12.5µM) of the derivatives (S. 18, 19 and 38) used to assay the ratio of 
rGSH/GSSG in the rat BT4Ca glioma cells. These lower concentrations (6.25 and 
12.5µM) presumably are not high enough to affect the intracellular GSH redox status. 
In contrast, treatment with 5-FUrd as well as the derivatives S. 98 and S.101 lead to a 
decrease of the ratio of rGSH/GSSG in the rat BT4Ca glioma cells (Fig. 51) accompanied 
by the elevated production of ROS as described. Moreover, incubation with S.98 clear-
ly excels the effect of 5-FUrd and causes an even higher level of oxidative stress for the 
rat BT4Ca glioma cells, with characteristic ROS increment. Thus, the treatment with 
S.98 leads to the consumption of almost every rGSH in the rat BT4Ca glioma cells. The 
low level of remaining antioxidants in the rat BT4Ca glioma cells presumably can’t bal-
ance the cellular redox status anymore; thereby the not bound ROS can contribute to 
the induction of apoptosis. 
Abnormalities in cellular signaling pathways can lead to the formation of tumors and 
thus, are critical for the transformation of healthy cells into malignantly growing and 
uncontrollable proliferating cancer cells. The nuclear factor kappa-light-chain-enhancer 
of activated B cells, i.e. NFκB, is an important redox regulated transcription factor and 
plays a central role for the intracellular signaling transduction. This huge protein com-
plex consists of several subunits including p65 and is present in almost every cell type. 
Upon different stimuli the subunit p65 translocates from the cytosol to the nucleus, 
where it leads to the transcription of e.g. cytokines, chemokines and adhesion mole-
cules (Perkins, 2007; Liu et al., 2017). Thus, by controlling the expression of different 
target genes, NFκB is involved in the pro- and anti-inflammatory cell response as well 
as proliferation, survival, and angiogenesis. For several tumor tissues an excessive acti-
vation of the NFκB-signaling pathway has been described, therefore linking NFκB acti-
vation to tumor pathogenesis (Xia et al., 2018). However, Lui et al. (2012) indicated a 
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suppressive role of NFκB in certain cancer types (Liu et al., 2012). Regarding this con-
troversy and to address the question, whether the induction of apoptosis and the ele-
vated production of ROS caused by our derivatives (described above) is mediated by 
NFκB, we analyzed the influence of our five selected derivatives on the activation of 
NFκB. Therefore, we determined the location of p65 within the rat BT4Ca glioma cells 
after the treatment (24 h) with 5-FUrd or the derivatives S. 18, 19, 38, 98 and 101 (12.5 
and 25 µM).  We could observe that the rat BT4Ca glioma cells do not show any activa-
tion of NFκB by translocation of p65 after the treatment (24 h) with neither 5-FUrd nor 
one of our derivatives of interest (Fig. 52 and supplements page 168-173, Fig. 46-51). 
We also tried to examine the activation of NFκB after the incubation of rat BT4Ca glio-
ma cells for 48 h, but due to the cytotoxic effects of the derivatives, a qualitative ana-
lysis of the cells was rather impossible. In addition to our results, it is described, that 5-
FU can even suppress NFκB in salivary gland cancer cells, leading to the induction of 
apoptosis (Azuma et al., 2001). Moreover, Voboril et al. (2004) indicated an increased 
sensitivity of colon cancer cells to 5-FU, due to the inhibition of NFκB. 
Another hallmark of cancer is the activation of tissue invasion and metastasis (Hana-
han & Weinberg, 2000 and 2011). The invasive migration ability of tumor cells is a 
basic requirement for metastasis and a characteristic of high tumor malignancy. There-
fore, an inhibitory effect towards the migration capacity of cancers cells is a beneficial 
feature for antitumor drugs. In this context, we examined the capacity for migration of 
rat BT4Ca glioma cells after treatment (6 h) with 5-FUrd or the five selected derivatives 
via a wound healing assay. Interestingly, the treatment with the derivatives S.18, 19, 
38 and 101 (12.5 and 25 µM) tend to result in an inhibition of the migration ability of 
the rat BT4Ca glioma cells, whereas 5-FUrd and the derivative S.98 do not (Fig. 54). 
Additionally, 5-FUrd and the derivatives induce apoptotic cell death. Apoptosis induces 
loss of cell adhesion, whereas necrosis does not affect cell adhesion (Kwon et al., 
2015). After apoptosis the adherent rat BT4Ca glioma cells detach from the ground 
with consequent loss of adhesion. Moreover, every time the culturing medium was 
moved by transport, it led to a further detachment of more cells. Hence, the non-
adherent cells could have influenced accurate measurement of migration. Due to 
these reasons, it is necessary to use an additional method for the examination of the 
migratory capability. For an accurate analysis, a new live-cell imaging assay is available, 
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as described by Restall et al. (2018). In the future this method would be suitable to 
measure the migration and invasion properties of the rat BT4Ca glioma cells during the 
treatment with 5-FUrd or the derivatives S. 18, 19, 38, 98 and 101. 
To investigate possible side effects, we also examined the impact of the derivatives on 
the viability of human, PMA differentiated macrophages (THP1). These cells are de-
rived out of monocytes from a patient with acute monocytic leukemia (DSMZ, 2019c). 
As a part of the cellular immune system, they are eligible to give a first impression of 
unwished secondary effects of the derivatives. We observed that the treatment with 
all five selected derivatives also have inhibitory effects on the viability of the THP1 cells 
at 12.5-50 µM, the highest concentrations tested (see supplements page 147, Fig. 22). 
How severe these side effects are for our immune system has to be examined in fur-
ther experiments. 
Beside the studies on different glioma cell lines, we also investigated the effects of the 
five selected derivatives on other tumor entities. Interestingly, the incubation with the 
derivatives S.18, 19, 38, 98 and 101 show also inhibitive effects on the viability of hu-
man colorectal carcinoma (HT29), human hepatocellular carcinoma (HepG2), human 
pancreas carcinoma (Panc-1) and murine renal carcinoma (RenCa) cells (see supple-
ments page 147-149, Fig. 23-26). Hence, the treatment with theses novelly synthesized 
derivatives reveal a wide range of anticancer effects. 
In this study we show for the first time that chemically modified derivatives, derived 
from nucleosides such as adenosine, formycin and inosine are able to keep up with or 
even overcome the cytostatic/cytotoxic effects of the well-known chemotherapeutic 
agent 5-FU. We suggest that the five selected derivatives S. 18, 19, 38, 98 and 101 are 
eligible for the treatment of different human glioma cell lines like GOS3, G28, G112, 
U251 and U87. Moreover, we demonstrate a broad range of the cytotoxcitiy of these 
derivatives on further carcinoma cell lines like HT29, HepG2, Panc-1 and RenCa. By 
exemplarily using the rat BT4Ca glioma cells we examine the cytotoxic effects of these 
derivatives in more detail. Therefore, we propose that these effects may be due to an 
increased level of intracellular oxidative stress that activates apoptotic signaling path-
ways mediating cell death. Remarkably, the intracellular proliferation signaling is addi-
tionally inhibited by the derivatives. Thus, these derivatives carry along some funda-
mental anti-cancer properties, which make them highly interesting as prospects for the 
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use as possible novel chemotherapeutic agents. Potentially, they could be used for the 
treatment of several different tumor entities, including highly aggressive tumors like 
glioma, pancreatic or other cancer types with bad prognosis. 
Further in vitro experiments have to be performed to proof our results and to provide 
a more detailed view on the mechanisms of action of these derivatives. It will be es-
sential to look at the protein expression of treated cells. Especially the expression pat-
tern of proteins, which are part of the signaling cascade of apoptosis e.g. different 
caspases or key proteins like p62 and Bax (Papaliagkas et al., 2007), or proteins in-
volved in the transmission of oxidative stress signaling like different MAP kinases, ERK 
or p38 and p53 would be of major interest (Martindale & Holbrook, 2002; Camhi et al., 
1995). Certainly, a detailed analysis of the expression of proteins, which regulate cell 
proliferation e.g. different cyclins or growth factors should also be examined (Duronio 
& Xiong, 2013). Additionally, it would be of great interest to study the long-term ef-
fects (above 48 h) of the derivatives and to look for possible induction/inhibition of 
drug resistance and cell recovery. For such investigations primary glioma cells obtained 
from patients after tumor resection should be considered. Furthermore, possible side 
effects of the derivatives towards healthy cells responsible for the detoxification like 
renal or liver cells should be investigated. In addition, the effects towards healthy neu-
rons or glia cells like astrocytes should also be analyzed. Following in vivo experiments, 
as well as clinical studies, respectively, have to be performed to clarify the potential of 
these novelly synthetized derivatives as chemotherapeutic drugs in detail. 
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6. Summary 
Today cancer is the second leading cause of death around the world. The World Health Organi-
zation predicts an increase from 9.6 million in 2018 up to 16.4 million cancer deaths in 2040. 
Although tumors of the brain and the nervous system are rather unusual among adults (2 %), 
they are the second most common diagnosed types of cancer in childhood.  
Gliomas and meningiomas are the most frequent types of brain tumors and account for 30 % 
of all tumors in the brain and central nervous system as well as for 80 % of all malignant intra-
cranial tumors. Usually surgical excision is the first step in the treatment of cancer followed by 
radio- and chemotherapy. Due to the mainly intracranial location of gliomas, surgical interven-
tions are extremely risky. Therefore, the use of radiation and chemotherapeutic agents be-
come more important. 
5-Fluorouracil (5-FU) is a well-known drug, usually used as chemotherapeutic agent in the 
standard treatment of fast proliferating cancer cells. Unfortunately, it carries along a wide 
range of unpleasant side effects in multiple organ systems. To improve the passage through 
the blood-brain-barrier and the cell membrane penetration thereby gaining a higher efficiency, 
our cooperation partners Prof. Dr. Rosemeyer and his colleagues from the Institute of Chemis-
try and Materials of the University of Osnabrück synthesized more than 120 novel nucleolipids. 
These molecules have been designed based on the 5-FU derivative 5-Fluorouridine (5-FUrd) or 
the nucleosides adenosine, cladribin, formycin, guanosine, inosine and others. The derivatives 
are modified at several positions and have different additional chemical side groups to mainly 
influence the hydrophilicity and lipophilicity and thus, to consequently improve the permeabil-
ity across the blood-brain-barrier as well as the uptake into the cells. 
At first we screened the impact of 5-FUrd and the 120 novelly synthesized derivatives on the 
viability of rat BT4Ca and human GOS3 glioma cells as well as differentiated human macro-
phages (THP1). Five derivatives (S.18, 19, 38, 98 and 101), which show low cytotoxic effects on 
the macrophages and are effective against both, the rat BT4Ca and the human GOS3 glioma 
cells, were selected to be further analyzed. Although we screened 120 derivatives consisting of 
purines and pyrimidines, it is remarkable that all five selected, most effective derivatives (S.18, 
19, 38, 98 and 101) belong to the group of pyrimidines. Comparing the chemical structure of 
the selected derivatives, the position of the attached farnesyl chain seems to be of high im-
portance for the effectiveness of the most efficient derivative (S.98) against rat as well as hu-
man glioma cell lines.  
We were able to show that the selected derivatives, derived out of the nucleosides adenosine 
(S.38), formycin (S.98) and inosine (S.18, 19 and 101) are able to keep up with or even over-
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come the cytostatic/cytotoxic effects of the well-known chemotherapeutic agent 5-FU on fur-
ther human glioma cell lines (G28, G112, U251 and U87) and several other tumor entities 
(HT29, HepG2, Panc-1 and RenCa). Certainly, these effects depend on the applied derivative as 
well as its concentration and vary among the specific cell type analyzed. Furthermore, using 
the rat BT4Ca glioma cells as a model of fast proliferating glioblastomas, we studied several 
intracellular mechanisms, possibly responsible for the examined cytotoxic effects of the se-
lected derivatives (S.18, 19, 38, 98 and 101).   
Our results indicate that the treatment of the rat BT4Ca glioma cells with each derivative lead 
to a concentration-dependent increase of the apoptotic cell rate. At concentrations 25 and 50 
µM each of the selected derivatives led to a distinct activation of the caspase 3, confirming the 
induction of apoptosis. We also observed an increase of the necrotic cell rate with ascending 
concentration (12.5, 25 and 50 µM) of each derivative presumably due to secondary necrosis. 
Beside the loss of cell mass due to apoptosis, we detected lower levels of PCNA after the 
treatment with any selected derivative (12.5 and 25 µM) indicating a reduced cell proliferation 
of the rat BT4Ca glioma cells. In contrast, the treatment of the rat BT4Ca glioma cells with 5-
FUrd did not affect the amount of PCNA. Thus, at our experimental conditions 5-FUrd showed 
no impact on the proliferation rate consistent with its cytostatic effects. Moreover, we deter-
mined a tremendous accumulation of ROS per cell after the treatment with each derivative (50 
µM). Especially the treatment with the derivatives S.18, 38 and 98 caused high oxidative stress 
in the rat BT4Ca glioma cells. But regarding the ratio of rGSH/GSSG only the derivative S.98 
showed an explicit effect on the glutathione antioxidant system by lowering the rGSH/GSSG 
ratio.  
Nevertheless, the activation of NFκB, through the translocation of the subunit p65 from the 
cytoplasm to the nucleus, was not triggered by the treatment with any selected derivative or 
5-FUrd. For a validation of the effects of the derivatives on the migratory capacity of the rat 
BT4Ca glioma cells during the treatment, further experiments need to be done with a more 
accurate method.  
The results indicate that our five selected derivatives S.18, 19, 38, 98 and 101 bear fundamen-
tal attributes, which are beneficial for the treatment of malignant cancer cells. These proper-
ties and the broad range of cytotoxicity as well as the inhibition of the cell proliferation make 
the five derivatives, especially S.19 and S.98, highly interesting as prospects against several 
tumor entities for the use as possible novel drugs with a high potential as chemotherapeutic 
agent. 
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6.1. Zusammenfassung 
Aktuell gehört Krebs zu den häufigsten Todesursachen weltweit. Die Welt-Gesundheits-
Organisation prognostiziert einen Anstieg von 9,5 Millionen Krebs assoziierten Todesfällen im Jahre 
2018 auf 16,4 Millionen im Jahre 2040. Obwohl Tumore des Gehirns und des zentralen Nervensys-
tems bei Erwachsenen eher selten vorkommen (2 %), sind sie bei Kindern die am zweithäufigsten 
diagnostizierte Krebsart. Gliome und Meningiome stellen 30 % aller Tumore des Gehirns und Zent-
ralen Nervensystems sowie 80 % aller bösartigen intrakranialen Tumore. Die Standardtherapie 
beginnt im Regelfall mit der operativen Entfernung, gefolgt von Radio- und Chemotherapie. Auf 
Grund der intrakranialen Lokalisation von Gliomen sind chirurgische Maßnahmen jedoch sehr ris-
kant, wodurch Bestrahlungen und chemotherapeutische Behandlungen an Bedeutung gewinnen. 
5-Fluorouracil (5-FU) ist ein seit vielen Jahren genutzter Wirkstoff, das als Chemotherapeutikum 
gegen schnell wachsende Krebszellen eingesetzt wird. Bedauerlicherweise bringt er auch ein brei-
tes Spektrum an unerwünschten Nebeneffekten für einige Organsysteme mit sich. Um die Passage 
durch die Blut-Hirn-Schranke und die Aufnahme in die Zelle und damit die Effektivität solcher Sub-
stanzen zu verbessern, entwickelten und synthetisierten unsere Kooperationspartner Prof. Dr. Ro-
semeyer und seine Kollegen am Institut für Chemie und Materialien der Universität Osnabrück über 
120 neue Nukleolipidderivate. Die Struktur dieser Nukleolipide beruht auf dem 5-FU Derivat 5-
Fluorouridine (5-FUrd) oder den Nukleosiden Adenosin, Cladribin, Formycin, Guanosin, Inosin und 
weiteren. Die Derivate dieser Grundsubstanzen sind an mehreren Positionen verändert und tragen 
zusätzlich verschiedene chemische Seitenketten um ihre Wasser- und Fettlöslichkeit zu beeinflus-
sen. Durch diese Modifikationen soll der Übergang durch die Blut-Hirn-Schranke sowie die Auf-
nahme in die Zelle erleichtert werden.  
Zu Beginn der Studie untersuchten wir den Einfluss von 5-FUrd und den 120 neu synthetisierten 
Derivaten auf die Viabilität der aus Ratten stammenden BT4Ca und humanen GOS3 Gliom Zellen 
sowie differenzierten humanen Makrophagen (THP1). Fünf Derivate (S.18, 19, 38, 98 und 101), die 
keine oder nur eine geringe schädliche Wirkung für die Makrophagen zeigten, gleichzeitig jedoch 
effektiv gegen beide Gliom Zelllinien (BT4Ca und GOS3) wirkten, wurden ausgewählt und weiter 
analysiert. Bemerkenswert ist, dass trotz der Anzahl von 120 getesteten Substanzen, die sowohl 
Purine als auch Pyrimidine einschlossen, alle fünf ausgewählten Derivate zur Gruppe der Pyrimidine 
gehören. Vergleicht man die chemische Struktur der ausgewählten Derivate, spielt die Position der 
angehängten Farnesylkette offenbar  eine wichtige Rolle für die Effektivität (S.98 versus S.18, 38 
und 101).  
Wir zeigen, dass die ausgewählten Derivate, deren Grundlage Adenosin (S.38), Formycin (S.98) und 
Inosin (S.18, 19, 101) bilden, einen vergleichbaren oder sogar stärkeren zytostati-
schen/zytotoxischen Effekt wie das bekannte chemotherapeutische Mittel 5-FU  haben. Auch bei 
weiteren untersuchten humanen Gliom Zellen (G28, G112, U251 und U87) und anderen Tumorenti-
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täten (HT29, HepG2, Panc-1 und RenCa) können wir diese Effekte beobachten. Diese sind abhängig 
vom eingesetzten Derivat sowie dessen Konzentration und des verwendeten, spezifischen Zelltyps. 
Für weiterführende Versuche wurden die Ratten BT4Ca Gliom Zellen exemplarisch als Model für 
schnellwachsende Glioblastomzellen verwendet. Wir analysierten unterschiedliche intrazelluläre 
Mechanismen, die möglicherweise an den bereits beobachteten zytotoxischen Wirkungen der fünf 
ausgewählten Derivate (S.18, 19, 38, 98 und 101) beteiligt sind.  
Unsere Versuchsergebnisse dokumentieren, dass die Behandlung der Ratten BT4Ca Gliom Zellen 
mit einem dieser fünf Derivate zu einem konzentrationsabhängigen Anstieg der apoptotischen 
Zellzahl führt. In den Konzentrationen 25 und 50 µM löst jedes der ausgewählten Derivate eine 
deutliche Steigerung der Capspase 3 Aktivität aus, wodurch die beobachtete Induktion der Apopto-
se bestätigt wird. Mit steigenden Konzentrationen (12.5, 25 und 50 µM) sehen wir allerdings auch 
einen erhöhten Anteil an nekrotischen Zellen. Dieser Anstieg ist vermutlich auf den Prozess der 
sekundär-Nekrose zurückzuführen. Neben dem Zelltod durch Apoptose, detektieren wir nach der 
Behandlung mit den jeweiligen Derivaten auch ein verringertes Level des Proteins PCNA, wodurch 
die Zellteilung der Ratten BT4Ca Zellen zusätzlich vermindert wird. Im Gegensatz zu den Derivaten 
hat die Behandlung mit 5-FUrd keinen Einfluss auf die gemessene Menge von PCNA. Demnach hat 
5-FUrd unter unseren experimentellen Bedingungen keinen Einfluss auf die Zellteilungsrate der 
Ratten BT4Ca Zellen, was den beobachteten zytostatischen Effekt von 5-FUrd erklärt. Darüber hin-
aus beobachten wir nach der Behandlung der Ratten BT4Ca Zellen mit den Derivaten (50 µM) eine 
enorme Anhäufung von Sauerstoff Radikalen (ROS) pro Zelle. Besonders der Einsatz der Derivate 
S.18, 38 und 98 verursacht hohen oxidativen Stress für die Ratten BT4Ca Zellen. Allerdings führt nur 
die Behandlung mit Derivat S.98 zu einer eindeutigen Verringerung des rGSH/GSSG Verhältnisses 
und beeinflusst damit die physiologisch zur Verfügung stehende Menge des Antioxidans Gluta-
thion. Keines der fünf ausgewählten Derivate führt zur Translokation der NFκB-Untereinheit p65 
vom Zytoplasma in den Zellkern und damit zur Aktivierung von NFκB in den Ratten BT4Ca Zellen. 
Der Einfluss der Derivate auf die Migration der Ratten BT4Ca Zellen muss durch weitere Untersu-
chungen validiert werden. Die bisherigen Analysen zeigen, dass die Derivate S.18, 19, 38, 98 und 
101 grundlegende Eigenschaften aufweisen, wodurch sie für die Behandlung von diversen bösarti-
gen Krebszellen geeignet sind. Die fünf ausgewählten Derivate, besonders, S.19 und S.98, tragen 
durch ihr breites zytotoxisches Wirkungsspektrum und die Hemmung der Zellteilungsrate ein hohes 
Potential gegen mehrere, unterschiedliche Tumorentitäten als neue Wirkstoffe im Bereich der 
Chemotherapie Verwendung zu finden.   
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